

10/27/00  
JCS57 U.S. PTO

10-30-00

A

09/14/01  
323869/60  
014 0 0 1181

Practitioner's Docket No. 47624-DIV (1417) **PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Box Patent Application**  
**Assistant Commissioner for Patents**  
**Washington, D.C. 20231**

**NEW APPLICATION TRANSMITTAL**

Transmitted herewith for filing is the patent application of  
Inventor(s): Jeffrey M. Isner; and Takayuki Asahara

**WARNING:** 37 C.F.R. § 1.41(a)(1) points out:

"(a) A patent is applied for in the name or names of the actual inventor or inventors.

(1) The inventorship of a nonprovisional application is that inventorship set forth in the oath or declaration as prescribed by § 1.63, except as provided for in § 1.53(d)(4) and § 1.63(d). If an oath or declaration as prescribed by § 1.63 is not filed during the pendency of a nonprovisional application, the inventorship is that inventorship set forth in the application papers filed pursuant to § 1.53(b), unless a petition under this paragraph accompanied by the fee set forth in § 1.17(i) is filed supplying or changing the name or names of the inventor or inventors."

For (title): **COMPOSITIONS AND METHODS FOR MODULATING VASCULARIZATION**

**CERTIFICATION UNDER 37 C.F.R. 1.10\***

(Express Mail label number is **mandatory**.)

(Express Mail certification is optional.)

I hereby certify that this correspondence and the documents referred to as attached therein are being deposited with the United States Postal Service on this date October 27, 2000 in an envelope as "Express Mail Post Office to Addressee," mailing Label Number EL300428605US, addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Patricia A. Barnes

(type or print name of person mailing paper)

Patricia A. Barnes

Signature of person mailing paper

**WARNING:** Certificate of mailing (first class) or facsimile transmission procedures of 37 C.F.R. 1.8 cannot be used to obtain a date of mailing or transmission for this correspondence.

**\*WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. 1.10(b).  
"Since the filing of correspondence under § 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

## 1. Type of Application

This new application is for a(n)

(check one applicable item below)

- ☒ Original (nonprovisional)  
☐ Design  
☐ Plant

**WARNING:** Do not use this transmittal for a completion in the U.S. of an International Application under 35 U.S.C. 371(c)(4), unless the International Application is being filed as a divisional, continuation or continuation-in-part application.

**WARNING:** Do not use this transmittal for the filing of a provisional application.

**NOTE:** If one of the following 3 items apply, then complete and attach ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF A PRIOR U.S. APPLICATION CLAIMED and a NOTIFICATION IN PARENT APPLICATION OF THE FILING OF THIS CONTINUATION APPLICATION.

- ☒ Divisional.  
☐ Continuation.  
☐ Continuation-in-part (C-I-P).

## 2. Benefit of Prior U.S. Application(s) (35 U.S.C. 119(e), 120, or 121)

**NOTE:** A nonprovisional application may claim an invention disclosed in one or more prior filed copending nonprovisional applications or copending international applications designating the United States of America. In order for a nonprovisional application to claim the benefit of a prior filed copending nonprovisional application or copending international application designating the United States of America, each prior application must name as an inventor at least one inventor named in the later filed nonprovisional application and disclose the named inventor's invention claimed in at least one claim of the later filed nonprovisional application in the manner provided by the first paragraph of 35 U.S.C. 112. Each prior application must also be:

(i) An international application entitled to a filing date in accordance with PCT Article 11 and designating the United States of America; or

(ii) Complete as set forth in § 1.51(b); or

(iii) Entitled to a filing date as set forth in § 1.53(b) or § 1.53(d) and include the basic filing fee set forth in § 1.16; or

(iv) Entitled to a filing date as set forth in § 1.53(b) and have paid therein the processing and retention fee set forth in § 1.21(f) within the time period set forth in § 1.53(f).

37 C.F.R. § 1.78(a)(1).

**NOTE:** If the new application being transmitted is a divisional, continuation or a continuation-in-part of a parent case, or where the parent case is an International Application which designated the U.S., or benefit of a prior provisional application is claimed, then check the following item and complete and attach ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED.

**WARNING:** If an application claims the benefit of the filing date of an earlier filed application under 35 U.S.C. 120, 121

or 365(c), the 20-year term of that application will be based upon the filing date of the earliest U.S. application that the application makes reference to under 35 U.S.C. 120, 121 or 365(c). (35 U.S.C. 154(a)(2) does not take into account, for the determination of the patent term, any application on which priority is claimed under 35 U.S.C. 119, 365(a) or 365(b).) For a c-i-p application, applicant should review whether any claim in the patent that will issue is supported by an earlier application and, if not, the applicant should consider canceling the reference to the earlier filed application. The term of a patent is not based on a claim-by-claim approach. See Notice of April 14, 1995, 60 Fed. Reg. 20,195, at 20,205.

**WARNING:** When the last day of pendency of a provisional application falls on a Saturday, Sunday, or Federal holiday within the District of Columbia, any nonprovisional application claiming benefit of the provisional application **must** be filed prior to the Saturday, Sunday, or Federal holiday within the District of Columbia. See 37 C.F.R. § 1.78(a)(3).

- ☒ The new application being transmitted claims the benefit of prior U.S. application(s).  
Enclosed are ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE  
BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED.

### 3. Papers Enclosed

#### A. Required for Filing Date under 37 C.F.R. § 1.53(b) (Regular) or 37 C.F.R. § 1.153 (Design) Application

43 Pages of Specification  
8 Pages of Claims  
10 Sheets of Drawing

**WARNING:** **DO NOT** submit original drawings. A high quality copy of the drawings should be supplied when filing a patent application. The drawings that are submitted to the Office must be on strong, white, smooth, and non-shiny paper and meet the standards according to § 1.84. If corrections to the drawings are necessary, they should be made to the original drawing and a high-quality copy of the corrected original drawing then submitted to the Office. Only one copy is required or desired. For comments on proposed then-new 37 C.F.R. 1.84, see Notice of March 9, 1988. (1990 O.G. 57-62).

**NOTE:** "Identifying indicia, if provided, should include the application number or the title of the invention, inventor's name, docket number (if any), and the name and telephone number of a person to call if the Office is unable to match the drawings to the proper application. This information should be placed on the back of each sheet of drawing a minimum distance of 1.5 cm. (5/8 inch) down from the top of the page. . . " 37 C.F.R. § 1.84(c).

(complete the following, if applicable)

- ☐ The enclosed drawing(s) are photograph(s), and there is also attached a "PETITION TO ACCEPT PHOTOGRAPH(S) AS DRAWING(S)." 37 C.F.R. § 1.84(b).
- ☐ Formal  
☒ Informal

#### B. Other Papers Enclosed

4 Pages of declaration and power of attorney  
1 Pages of Abstract  
1 Other - Application cover sheet

#### 4. Additional Papers Enclosed

- ☐ Amendment to claims
- ☐ Cancel in this applications claims \_\_\_\_\_ before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)
- ☐ Add the claims shown on the attached amendment. (Claims added have been numbered consecutively following the highest numbered original claims.)
- ☒ Preliminary Amendment
- ☐ Information Disclosure Statement (37 C.F.R. § 1.98)
- ☐ Form PTO-1449 (PTO/SB/08A and 08B)
- ☐ Citations
- ☐ Declaration of Biological Deposit
- ☐ Submission of "Sequence Listing," computer readable copy and/or amendment pertaining thereto for biotechnology invention containing nucleotide and/or amino acid sequence.
- ☐ Authorization of Attorney(s) to Accept and Follow Instructions from Representative
- ☐ Special Comments
- ☐ Other

#### 5. Declaration or Oath (including power of attorney)

**NOTE:** A newly executed declaration is not required in a continuation or divisional application provided the prior nonprovisional application contained a declaration as required, the application being filed is by all or fewer than all the inventors named in the prior application, there is no new matter in the application being filed, and a copy of the executed declaration filed in the prior application (showing the signature or an indication thereon that it was signed) is submitted. The copy must be accompanied by a statement requesting deletion of the names of person(s) who are not inventors of the application being filed. If the declaration in the prior application was filed under § 1.47 then a copy of that declaration must be filed accompanied by a copy of the decision granting § 1.47 status or, if a nonsigning person under § 1.47 has subsequently joined in a prior application, then a copy of the subsequently executed declaration must be filed. See 37 C.F.R. § 1.63(d)(1)-(3).

**NOTE:** A declaration filed to complete an application must be executed, identify the specification to which it is directed, identify each inventor by full name, including the family name, and at least one given name without abbreviation together with any other given name or initial, and the residence, post office address and country of citizenship of each inventor, and state whether the inventor is a sole or joint inventor. 37 C.F.R. § 1.63(a)(1)-(4).

☒ Enclosed – Copy from prior application (USSN 09/265,041 with Power of Attorney.

Executed by

(check all applicable boxes)

- ☒ inventor(s).
- ☐ legal representative of inventor(s). 37 C.F.R. § 1.42 or 1.43.
- ☐ joint inventor or person showing a proprietary interest on behalf of inventor who refused to sign or cannot be reached.

☐ This is the petition required by 37 C.F.R. § 1.47 and the statement required by 37 C.F.R. § 1.47 is also attached. See item 13 below for fee.

☐ Not Enclosed.

**NOTE:** *Where the filing is a completion in the U.S. of an International Application, or where the completion of the U.S. application contains subject matter in addition to the International Application, the application may be treated as a continuation or continuation-in-part, as the case may be, utilizing ADDED PAGE FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION CLAIMED.*

☐ Application is made by a person authorized under 37 C.F.R. 1.41(c) on behalf of all the above named inventor(s).

*(The declaration or oath, along with the surcharge required by 37 C.F.R. § 1.16(e), can be filed subsequently).*

☐ Showing that the filing is authorized.  
*(not required unless called into question. 37 C.F.R. § 1.41(d))*

## 6. Inventorship Statement

**WARNING:** *If the named inventors are each not the inventors of all the claims an explanation, including the ownership of the various claims at the time the last claimed invention was made, should be submitted.*

The inventorship for all the claims in this application are:

☒ The same.

or

☐ Not the same. An explanation, including the ownership of the various claims at the time the last claimed invention was made,  
☐ is submitted.  
☐ will be submitted.

## 7. Language

**NOTE:** *An application including a signed oath or declaration may be filed in a language other than English. An English translation of the non-English language application and the processing fee of \$130.00 required by 37 C.F.R. § 1.17(k) is required to be filed with the application, or within such time as may be set by the Office. 37 C.F.R. § 1.52(d).*

☒ English

☐ Non-English

☐ The attached translation includes a statement that the translation is accurate. 37 C.F.R. § 1.52(d).

## 8. Assignment

☒ An assignment of the invention to St. Elizabeth's Medical Center was recorded at the USPTO on 05/24/99 at Reel 009989, Frame 0438.

☐ is attached. A separate ☐ "COVER SHEET FOR ASSIGNMENT (DOCUMENT) ACCOMPANYING NEW PATENT APPLICATION" or ☐ FORM PTO 1595 is also attached.

☐ will follow.

**NOTE:** "If an assignment is submitted with a new application, send two separate letters-one for the application and one for the assignment" Notice of May 4, 1990 (1114 O.G. 77-78).

**WARNING:** A newly executed "STATEMENT UNDER 37 C.F.R. § 3.73(b)" must be filed when a continuation-in-part application is filed by an assignee. Notice of April 30, 1993, 1150 O.G. 62-64.

## 9. Certified Copy

Certified copy(ies) of application(s)

Country	Appln. no.	Filed
Country	Appln. no.	Filed
Country	Appln. no.	Filed

from which priority is claimed

☐ is (are) attached.

☐ will follow.

**NOTE:** The foreign application forming the basis for the claim for priority must be referred to in the oath or declaration. 37 C.F.R. § 1.55(a) and 1.63.

**NOTE:** This item is for any foreign priority for which the application being filed directly relates. If any parent U.S. application or International Application from which this application claims benefit under 35 U.S.C. 120 is itself entitled to priority from a prior foreign application, then complete item 18 on the ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED.

## 10. Fee Calculation (37 C.F.R. § 1.16)

A. ☒ Regular application

CLAIMS AS FILED

Claims	Number Filed	Basic Fee Allowance	Number Extra	Rate	Basic Fee 37 C.F.R. § 1.16(a) \$710.00
<hr/>					
Total Claims (37 C.F.R. § 1.16(c))	33	- 20 =	13 x	\$ 18.00	\$ 234.00
<hr/>					
Independent Claims (37 C.F.R. § 1.16(b))	3	- 3 =	-0- x	\$ 80.00	\$ -0-
<hr/>					
Multiple Dependent Claim(s), if any (37 C.F.R. § 1.16(d))	-0-		+	\$ 270.00	\$ -0-
<hr/>					

- ☐ Amendment cancelling extra claims is enclosed.  
☐ Amendment deleting multiple-dependencies is enclosed.  
☐ Fee for extra claims is not being paid at this time.

*NOTE: If the fees for extra claims are not paid on filing they must be paid or the claims cancelled by amendment, prior to the expiration of the time period set for response by the Patent and Trademark Office in any notice of fee deficiency. 37 C.F.R. § 1.16(d).*

Filing Fee Calculation      \$ 944.00

- B. ☐ Design application  
(\$310.00—37 C.F.R. § 1.16(f))      Filing Fee Calculation      \$ \_\_\_\_\_
- C. ☐ Plant application  
(\$480.00—37 C.F.R. § 1.16(g))      Filing Fee Calculation      \$ \_\_\_\_\_

**11. Small Entity Statement(s)**

- ☐ Statement(s) that this is a filing by a small entity under 37 C.F.R. §§ 1.9 and 1.27 is (are) attached.

**WARNING:** "Status as a small entity must be specifically established in each application or patent in which the status is available and desired. Status as a small entity in one application or patent does not affect any other application or patent, including applications or patents which are directly or indirectly dependent upon the application or patent in which the status has been established. The refiling of an application under § 1.53 as a continuation, division, or continuation-in-part (including a continued prosecution application under § 1.53(d)), or the filing of a reissue application requires a new





(\$40.00; 37 C.F.R. § 1.21(h))  
(See attached "COVER SHEET FOR  
ASSIGNMENT ACCOMPANYING NEW  
APPLICATION.")

\$ \_\_\_\_\_

- ☐ Petition fee for filing by other  
than all the inventors or person  
on behalf of the inventor where  
inventor refused to sign or cannot  
be reached

(\$130.00; 37 C.F.R. §§ 1.47 and 1.17(i))

\$ \_\_\_\_\_

- ☐ For processing an application with a  
specification in a non-English language  
(\$130.00; 37 C.F.R. §§ 1.52(d) and 1.17(k))

\$ \_\_\_\_\_

- ☐ Processing and retention fee  
(\$130.00; 37 C.F.R. §§ 1.53(d) and 1.21(l))

\$ \_\_\_\_\_

- ☐ Fee for international-type search report  
(\$40.00; 37 C.F.R. § 1.21(e))

\$ \_\_\_\_\_

*NOTE: 37 C.F.R. § 1.21(l) establishes a fee for processing and retaining any application that is abandoned for failing to complete the application pursuant to 37 C.F.R. § 1.53(f) and this, as well as the changes to 37 C.F.R. § 1.53 and 1.78(a)(1), indicate that in order to obtain the benefit of a prior U.S. application, either the basic filing fee must be paid, or the processing and retention fee of § 1.21(l) must be paid, within 1 year from notification under § 53(f).*

Total Fees Enclosed

\$ 472.00

#### 14. Method of Payment of Fees

☒ Check in the amount of \$ 472.00.

☐ Charge Account No. \_\_\_\_\_ in the amount of \$ \_\_\_\_\_.  
A duplicate of this transmittal is attached.

*NOTE: Fees should be itemized in such a manner that it is clear for which purpose the fees are paid. 37 C.F.R. § 1.22(b).*

#### 15. Authorization to Charge Additional Fees

**WARNING:** If no fees are to be paid on filing, the following items should not be completed.

**WARNING:** Accurately count claims, especially multiple dependent claims, to avoid unexpected high charges, if extra claim charges are authorized.

☒ The Commissioner is hereby authorized to charge the following additional fees by this paper and during the entire pendency of this application to Account No. 04-1105.

☒ 37 C.F.R. § 1.16(a), (f) or (g) (filing fees)

☒ 37 C.F.R. § 1.16(b), (c) and (d) (presentation of extra claims)

NOTE: Because additional fees for excess or multiple dependent claims not paid on filing or on later presentation must only be paid or these claims cancelled by amendment prior to the expiration of the time period set for response by the PTO in any notice of fee deficiency (37 C.F.R. § 1.16(d)), it might be best not to authorize the PTO to charge additional claim fees, except possibly when dealing with amendments after final action.

☐ 37 C.F.R. § 1.16(e) (surcharge for filing the basic filing fee and/or declaration on a date later than the filing date of the application)

☐ 37 C.F.R. § 1.17(a)(1)-(5) (extension fees pursuant to § 1.136(a).

☒ 37 C.F.R. § 1.17 (application processing fees)

NOTE: "A written request may be submitted in an application that is an authorization to treat any concurrent or future reply, requiring a petition for an extension of time under this paragraph for its timely submission, as incorporating a petition for extension of time for the appropriate length of time. An authorization to charge all required fees, fees under § 1.17, or all required extension of time fees will be treated as a constructive petition for an extension of time in any concurrent or future reply requiring a petition for an extension of time under this paragraph for its timely submission. Submission of the fee set forth in § 1.17(a) will also be treated as a constructive petition for an extension of time in any concurrent reply requiring a petition for an extension of time under this paragraph for its timely submission." 37 C.F.R. § 1.136(a)(3).

☐ 37 C.F.R. § 1.18 (issue fee at or before mailing of Notice of Allowance, pursuant to 37 C.F.R. § 1.311(b))

NOTE: Where an authorization to charge the issue fee to a deposit account has been filed before the mailing of a Notice of Allowance, the issue fee will be automatically charged to the deposit account at the time of mailing the notice of allowance. 37 C.F.R. § 1.311(b)).

NOTE: 37 C.F.R. § 1.28(b) requires "Notification of any change in status resulting in loss of entitlement to small entity status must be filed in the application . . . prior to paying, or at the time of paying, . . . issue fee." From the wording of 37 C.F.R. § 1.28(b), (a) notification of change of status must be made even if the fee is paid as "other than a small entity" and (b) no notification is required if the change is to another small entity.

## 16. Instructions as to Overpayment

NOTE: "... Amounts of twenty-five dollars or less will not be returned unless specifically requested within a reasonable time, nor will the payer be notified of such amounts; amounts over twenty-five dollars may be returned by check or, if requested, by credit to a deposit account." 37 C.F.R. § 1.26(a).

☒ Credit Account No. 04-1105.

☐ Refund



**SIGNATURE OF PRACTITIONER**

Reg. No. 40,927

Tel. No.: (617) 523-3400

Customer No.: 21874

Robert L. Buchanan

*(type or print name of practitioner)*

EDWARDS & ANGELL, LLP

DIKE, BRONSTEIN, ROBERTS &  
CUSHMAN

Intellectual Property Practice Group

130 Water Street

P.O. Address

Boston, MA 02109

**[X] Incorporation by reference of added pages**

*(check the following item if the application in this transmittal claims the benefit of prior U.S. application(s) (including an international application entering the U.S. stage as a continuation, divisional or C-I-P application) and complete and attach the ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED)*

**[X] Plus Added Pages for New Application Transmittal Where Benefit of Prior U.S. Application(s) Claimed**

Number of pages added 5

**[X] Plus Added Pages for Papers Referred to in Item 4 Above**

Number of pages added 2

**[ ] Plus added pages deleting names of inventor(s) named on prior application(s) who is/are no longer inventor(s) of the subject matter claimed in this application.**

Number of pages added \_\_\_\_\_

[ ] Plus "Assignment Cover Letter Accompanying New Application"

Number of pages added \_\_\_\_\_

[ ] **Statement Where No Further Pages Added**

*(if no further pages form a part of this Transmittal, then end this Transmittal with this page and check the following item)*

[ ] This transmittal ends with this page.



# **ADDED PAGES FOR APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED**

NOTE: See 37 C.F.R. § 1.78.

## **17. Relate Back**

**WARNING:** *If an application claims the benefit of the filing date of an earlier filed application under 35 U.S.C. 120, 121 or 365(c), the 20-year term of that application will be based upon the filing date of the earliest U.S. application that the application makes reference to under 35 U.S.C. 120, 121 or 365(c). (35 U.S.C. 154(a)(2) does not take into account, for the determination of the patent term, any application on which priority is claimed under 35 U.S.C. 119, 365(a) or 365(b).) For a c-i-p application, applicant should review whether any claim in the patent that will issue is supported by an earlier application and, if not, the applicant should consider canceling the reference to the earlier filed application. The term of a patent is not based on a claim-by-claim approach. See Notice of April 14, 1995, 60 Fed. Reg. 20,195, at 20,205.*

*(complete the following, if applicable)*

☒ Amend the specification by inserting, before the first line, the following sentence:

## **A. 35 U.S.C. 119(e)**

NOTE: *"Any nonprovisional application claiming the benefit of one or more prior filed copending provisional applications must contain or be amended to contain in the first sentence of the specification following the title a reference to each such prior provisional application, identifying it as a provisional application, and including the provisional application number (consisting of series code and serial number)." 37 C.F.R. § 1.78(a)(4).*

☐ "This application claims the benefit of U.S. Provisional Application(s) No(s).:

**APPLICATION NO(S):**

**FILING DATE**

\_\_\_\_\_/\_\_\_\_\_  
\_\_\_\_\_/\_\_\_\_\_  
\_\_\_\_\_/\_\_\_\_\_

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

## **B. 35 U.S.C. 120, 121 and 365(c)**

NOTE: *"Except for a continued prosecution application filed under § 1.53(d), any nonprovisional application claiming the benefit of one or more prior filed copending nonprovisional applications or international applications designating the United States of America must contain or be amended to contain in the first sentence of the specification following the title a reference to each such prior application, identifying it by application number (consisting of the series code and serial number) or international application number and international filing date and indicating the relationship of the applications. . . . Cross-references to other related applications may be made when appropriate." (See § 1.14(a)). 37 C.F.R. § 1.78(a)(2).*

☒ "This application is a

☐ continuation

☐ continuation-in-part

☒ divisional

of copending application(s)

☒ application number 09/265,041 filed on March 9, 1999

☐ International Application \_\_\_\_\_ filed on \_\_\_\_\_ and which designated the U.S."

NOTE: The proper reference to a prior filed PCT application that entered the U.S. national phase is the U.S. serial number and the filing date of the PCT application that designated the U.S.

NOTE: (1) Where the application being transmitted adds subject matter to the International Application, then the filing can be as a continuation-in-part or (2) if it is desired to do so for other reasons then the filing can be as a continuation.

NOTE: The deadline for entering the national phase in the U.S. for an international application was clarified in the Notice of April 28, 1987 (1079 O.G. 32 to 46) as follows:

"The Patent and Trademark Office considers the International application to be pending until the 22nd month from the priority date if the United States has been designated and no Demand for International Preliminary Examination has been filed prior to the expiration of the 19th month from the priority date and until the 32nd month from the priority date if a Demand for International Preliminary Examination which elected the United States of America has been filed prior to the expiration of the 19th month from the priority date, provided that a copy of the international application has been communicated to the Patent and Trademark Office within the 20 or 30 month period respectively. If a copy of the international application has not been communicated to the Patent and Trademark Office within the 20 or 30 month period respectively, the international application becomes abandoned as to the United States 20 or 30 months from the priority date respectively. These periods have been placed in the rules as paragraph (h) of § 1.494 and paragraph (i) of § 1.495. A continuing application under 35 U.S.C. 365(c) and 120 may be filed anytime during the pendency of the international application."

☒ "The nonprovisional application designated above, namely application 09/265,041, filed March 9, 1999, claims the benefit of U.S. Provisional Application(s) No(s):

APPLICATION NO(S):

FILING DATE

60 / 077,262  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

March 9, 1998     "  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_     "

☐ Where more than one reference is made above please combine all references into one sentence.

### 18. Relate Back—35 U.S.C. 119 Priority Claim for Prior Application

The prior U.S. application(s), including any prior International Application designating the U.S., identified above in item 17B, in turn itself claim(s) foreign priority(ies) as follows:

Country	Appln. no.	Filed
The certified copy(ies) has (have)		
<input type="checkbox"/> been filed on _____, in prior application 0 / _____, which was filed on _____		
<input type="checkbox"/> is (are) attached.		

**WARNING:** The certified copy of the priority application that may have been communicated to the PTO by the International Bureau may not be relied on without any need to file a certified copy of the priority application in the continuing application. This is so because the certified copy of the priority application communicated by the International Bureau is placed in a folder and is not assigned a U.S. serial number unless the national stage is entered. Such folders are disposed of if the national stage is not entered. Therefore, such certified copies may not be available if needed later in the prosecution of a continuing application. An alternative would be to physically remove the priority documents from the folders and transfer them to the continuing application. The resources required to request transfer, retrieve the folders, make suitable record notations, transfer the certified copies, enter and make a record of such copies in the Continuing Application are substantial. Accordingly, the priority documents in folders of international applications that have not entered the national stage may not be relied on. Notice of April 28, 1987 (1079 O.G. 32 to 46).

### 19. Maintenance of Dependancy of Prior Application

**NOTE:** The PTO finds it useful if a copy of the petition filed in the prior application extending the term for response is filed with the papers constituting the filing of the continuation application. Notice of November 5, 1985 (1060 O.G. 27).

**A. ☐ Extension of time in prior application**

*(This item must be completed and the papers filed in the prior application, if the period set in the prior application has run.)*

☐ A petition, fee and response extends the term in the pending **prior** application until \_\_\_\_\_

☐ A copy of the petition filed in prior application is attached.

**B. ☐ Conditional Petition for Extension of Time in Prior Application**

*(complete this item, if previous item not applicable)*

☐ A conditional petition for extension of time is being filed in the pending **prior** application.

☐ A copy of the conditional petition filed in the prior application is attached.

**20. Further Inventorship Statement Where Benefit of Prior Application(s) Claimed**

*(complete applicable item (a), (b) and/or (c) below)*

- (a) ☒ This application discloses and claims only subject matter disclosed in the prior application whose particulars are set out above and the inventor(s) in this application are

☒ the same.

☐ less than those named in the prior application. It is requested that the following inventor(s) identified for the prior application be deleted:

---

*(type name(s) of inventor(s) to be deleted)*

- (b) ☐ This application discloses and claims additional disclosure by amendment and a new declaration or oath is being filed. With respect to the prior application, the inventor(s) in this application are

☐ the same.

☐ the following additional inventor(s) have been added:

---

*(type name(s) of inventor(s) to be deleted)*

- (c) ☒ The inventorship for all the claims in this application are

☒ the same.

☐ not the same. An explanation, including the ownership of the various claims at the time the last claimed invention was made

☐ is submitted.

☐ will be submitted.

**21. Abandonment of Prior Application *(if applicable)***

- ☐ Please abandon the prior application at a time while the prior application is pending, or when the petition for extension of time or to revive in that application is granted, and when this application is granted a filing date, so as to make this application copending with said prior application.

**NOTE:** *According to the Notice of May 13, 1983 (103, TMOG 6-7), the filing of a continuation or continuation-in-part application is a proper response with respect to a petition for extension of time or a petition to revive and should include the express abandonment of the prior application conditioned upon the granting of the petition and the granting of a filing date to the continuing application.*



## 22. Petition for Suspension of Prosecution for the Time Necessary to File an Amendment

**WARNING:** *"The claims of a new application may be finally rejected in the first Office action in those situations where (1) the new application is a continuing application of, or a substitute for, an earlier application, and (2) all the claims of the new application (a) are drawn to the same invention claimed in the earlier application, and (b) would have been properly finally rejected on the grounds of art of record in the next Office action if they had been entered in the earlier application." MPEP, § 706.07(b), 6th ed., rev.2.*

**NOTE:** *Where it is possible that the claims on file will give rise to a first action final for this continuation application and for some reason an amendment cannot be filed promptly (e.g., experimental data is being gathered) it may be desirable to file a petition for suspension of prosecution for the time necessary.*

*(check the next item, if applicable)*

☐ There is provided herewith a Petition To Suspend Prosecution for the Time Necessary to File an Amendment (New Application Filed Concurrently)

## 23. Small Entity (37 CFR § 1.28(a))

☒ Applicant has established small entity status by the filing of a statement in parent application 09/265,041 on May 20, 1999.

☒ A copy of the statement previously filed is included.

**WARNING:** See 37 CFR § 1.28(a).

## 24. NOTIFICATION IN PARENT APPLICATION OF THIS FILING

☒ A notification of the filing of this  
*(check one of the following)*

☐ continuation

☐ continuation-in-part

☒ divisional

is being filed in the parent application, from which this application claims priority under 35 U.S.C. § 120.

Docket No.  
47624 (1417)

Serial No.

09265,041

Filing Date

**March 9, 1999**

Patent No.

Issue Date

**Applicant/** Jeffrey M. Isner; and Takayuki Asahara  
**Patentee:**

Invention: COMPOSITIONS AND METHODS FOR MODULATING VASCULARIZATION

09/698323  
10/27/00

I hereby declare that I am an official empowered to act on behalf of the nonprofit organization identified below:

NAME OF ORGANIZATION: **St. Elizabeth's Medical Center of Boston, Inc.**

ADDRESS OF ORGANIZATION: 736 Cambridge Street  
Boston, MA 02135

## TYPE OF NONPROFIT ORGANIZATION:

- ☐ University or other Institute of Higher Education
- ☒ Tax Exempt under Internal Revenue Service Code (26 U.S.C. 501(a) and 501(c)(3))
- ☐ Nonprofit Scientific or Educational under Statute of State of The United States of America  
Name of State: Citation of Statute:
- ☐ Would Qualify as Tax Exempt under Internal Revenue Service Code (26 U.S.C. 501(a) and 501(c)(3)) if Located in The United States of America
- ☐ Would Qualify as Nonprofit Scientific or Educational under Statute of State of The United States of America if Located in The United States of America  
Name of State: Citation of Statute:

I hereby declare that the above-identified nonprofit organization qualifies as a nonprofit organization as defined in 37 C.F.R. 1.9(e) for purposes of paying reduced fees to the United States Patent and Trademark Office regarding the invention described in:

- ☐ the specification to be filed herewith.  
☒ the application identified above.  
☐ the patent identified above.

I hereby declare that rights under contract or law have been conveyed to and remain with the nonprofit organization with regard to the above identified invention.

If the rights held by the above-identified nonprofit organization are not exclusive, each individual, concern or organization having rights to the invention is listed on the next page and no rights to the invention are held by any person, other than the inventor, who could not qualify as an independent inventor under 37 CFR 1.9(c) or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

Each person, concern or organization to which I have assigned, granted, conveyed, or licensed or am under an obligation under contract or law to assign, grant, convey, or license any rights in the invention is listed below:

- ☒ no such person, concern or organization exists.  
☐ each such person, concern or organization is listed below.

FULL NAME

ADDRESS

☐ Individual☐ Small Business Concern☐ Nonprofit Organization

FULL NAME

ADDRESS

☐ Individual☐ Small Business Concern☐ Nonprofit Organization

FULL NAME

ADDRESS

☐ Individual☐ Small Business Concern☐ Nonprofit Organization

FULL NAME

ADDRESS

☐ Individual☐ Small Business Concern☐ Nonprofit Organization

Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING:

John Fitzgerald

TITLE IN ORGANIZATION:

Vice President, Finance

ADDRESS OF PERSON SIGNING:

736 Cambridge StreetBoston, MA 02135

SIGNATURE:



DATE:

5/13/99

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**APPLICANT:** Jeffrey M. Isner, et al.

**EXAMINER:**

**SERIAL NO.**

**GROUP:**

**FILED:** Herewith  
(Divisional Appl. of USSN. 09/265,041 filed on 03/09/99)

**FOR:** COMPOSITIONS AND METHODS FOR MODULATING  
VASCULARIZATION

.....  
CERTIFICATE OF EXPRESS MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on October 27, 2000, in an envelope as "Express Mail Post Office To Addressee", mailing Label Number EL300428605US, addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

By: Patricia A. Barnes  
Patricia A. Barnes

.....  
Sir:

PRELIMINARY AMENDMENT

Please amend the above-identified application as follows:

IN THE CLAIMS:

Kindly cancel claims 32-43, and 44-47 without prejudice.

REMARKS

Consideration of this Preliminary Amendment is requested prior to examination of the above-captioned application.

Early consideration and allowance of the above-captioned application is respectfully requested.

Respectfully submitted,



---

Robert L. Buchanan  
Patent Agent  
Registration No. 40,927  
EDWARDS & ANGELL, LLP  
DIKE, BRONSTEIN, ROBERTS  
& CUSHMAN  
Intellectual Property Practice Group  
130 Water Street  
Boston, MA 02109-4280  
Tel. (617) 523-3400

Date: 10/27, 2000

#144283

[illegible]Express Mail Label No. **EL300428605US**

TITLE: COMPOSITIONS AND METHODS FOR MODULATING VASCULARIZATION

ATTORNEY: David G. Conlin (Reg. No. 27,026)  
Robert L. Buchanan (Reg. No. 40,927)  
DIKE, BRONSTEIN, ROBERTS  
& CUSHMAN, LLP  
130 Water Street  
Boston, Massachusetts 02109  
Tel: (617) 523-3400  
Fax: (617) 523-6440

COMPOSITIONS AND METHODS FOR MODULATING VASCULARIZATION

CROSS REFERENCE TO RELATED APPLICATION

The present application is a continuation of U.S. Provisional Application No. 60/077,262, filed on March 9, 1998; the disclosure of which is hereby incorporated by reference.

STATEMENT OF GOVERNMENT INTEREST

Funding for the present invention was provided in part by the Government of the United States by virtue of grants HL 40518, HL02824 and HL57516 by the National Institutes of Health. Accordingly, the Government of the United States has certain rights in and to the invention claimed herein.

FIELD OF THE INVENTION

The present invention relates to methods for modulating vascularization particularly in a mammal. In one aspect, methods are provided for modulating vascularization that includes administering to the mammal an effective amount of granulocyte macrophage-colony stimulating factor (GM-CSF). Further provided are methods for treating or detecting damaged blood vessels in the mammal. The invention has a wide spectrum of useful applications including inducing formation of new blood vessels in the mammal.

BACKGROUND OF THE INVENTION

There is nearly universal recognition that blood vessels help supply oxygen and nutrients to living tissues. Blood vessels also facilitate removal of waste products. Blood vessels are renewed by a process termed "angiogenesis". See generally Folkman and Shing, *J. Biol. Chem.* 267 (16), 10931-10934 (1992).

Angiogenesis is understood to be important for the well-being of most mammals. As an illustration, angiogenesis has been disclosed as being an essential process for reproduction, development and wound repair.

5           There have been reports that inappropriate angiogenesis can have severe consequences. For example, it has been disclosed that solid tumor growth is facilitated by vascularization. There is broad support for the concept that mammals must regulate angiogenesis extensively.

10           There has been much attention directed to understanding how angiogenesis is controlled. In particular, angiogenesis is believed to begin with the degradation of the basement membrane by proteases secreted from endothelial cells (EC) activated by mitogens, e.g., vascular endothelial growth factor (ie. VEGF-1), basic fibroblast growth factor (bFGF) and/or others. The  
15           cells migrate and proliferate, leading to the formation of solid endothelial cell sprouts into the stromal space, then, vascular loops are formed and capillary tubes develop with formation of tight junctions and deposition of new basement membrane.

20           In adults, it has been disclosed that the proliferation rate of endothelial cells is typically low, compared to other cell types in the body. The turnover time of these cells can exceed one thousand days. Physiological exceptions in which angiogenesis results in rapid proliferation occurs under tight regulation are found in the female reproduction system and during wound healing. It has  
25           been reported that the rate of angiogenesis involves a change in the local equilibrium between positive and negative regulators of the growth of microvessels.

30           Abnormal angiogenesis is thought to occur when the body loses its control of angiogenesis, resulting in either excessive or insufficient blood vessel growth. For instance, conditions such as ulcers, strokes, and heart attacks may result from the absence of angiogenesis normally required for natural healing. In contrast, excessive blood vessel proliferation can facilitate tumor growth, blindness, psoriasis, rheumatoid arthritis, as well as other



medical conditions.

5       The therapeutic implications of angiogenic growth factors were first described by Folkman and colleagues over two decades ago (Folkman, *N. Engl. J. Med.*, 85:1182-1186 (1971)). Recent work has established the feasibility of using recombinant angiogenic growth factors, such as fibroblast growth factor (FGF) family (Yanagisawa-Miwa, et al., *Science*, 257:1401-1403 (1992) and Baffour, et al., *J Vasc Surg*, 16:181-91 (1992)), endothelial cell growth factor (ECGF)(Pu, et al., *J Surg Res*, 54:575-83 (1993)), and vascular endothelial  
10   growth factor (VEGF-1) to expedite and/or augment collateral artery development in animal models of myocardial and hindlimb ischemia (Takeshita, et al., *Circulation*, 90:228-234 (1994) and Takeshita, et al., *J Clin Invest*, 93:662-70 (1994)).

15       The feasibility of using gene therapy to enhance angiogenesis has received recognition. For example, there have been reports that angiogenesis can facilitate treatment of ischemia in a rabbit model and in human clinical trials. Particular success has been achieved using VEGF-1 administered as a balloon gene delivery system. Successful transfer and sustained expression of  
20   the VEGF-1 gene in the vessel wall subsequently augmented neovascularization in the ischemic limb (Takeshita, et al., *Laboratory Investigation*, 75:487-502 (1996); Isner, et al., *Lancet*, 348:370 (1996)). In addition, it has been reported that direct intramuscular injection of DNA encoding VEGF-1 into ischemic tissue induces angiogenesis, providing the  
25   ischemic tissue with increased blood vessels (Tsurumi et al., *Circulation*, 94(12):3281-3290 (1996)).

      Alternative methods for promoting angiogenesis are desirable for a number of reasons. For example, it is believed that native endothelial  
30   progenitor cell (EPC) number and/or viability decreases over time. Thus, in certain patient populations, e.g., the elderly, EPCs capable of responding to angiogenic proteins may be limited. Also, such patients may not respond well to conventional therapeutic approaches.

There have been reports that at least some of these problems can be reduced by administering isolated EPCs to patients and especially those undergoing treatment for ischemic disease. However, this suggestion is believed to be prohibitively expensive as it can require isolation and

5 maintenance of patient cells. Moreover, handling of patient cells can pose a significant health risk to both the patient and attending personnel in some circumstances.

Granulocyte macrophage colony stimulating factor (GM-CSF) has been shown to exert a regulatory effect on granulocyte-committed progenitor cells to

10 increase circulating granulocyte levels (Gasson, J.C., *Blood* 77:1131 (1991). In particular, GM-CSF acts as a growth factor for granulocyte, monocyte and eosinophil progenitors.

Administration of GM-CSF to human and non-human primates results in increased numbers of circulating neutrophils, as well as eosinophils,

15 monocytes and lymphocytes. Accordingly, GM-CSF is believed to be particularly useful in accelerating recovery from neutropenia in patients subjected to radiation or chemotherapy, or following bone marrow transplantation. In addition, although GM-CSF is less potent than other cytokines, e.g., FGF, in promoting EC proliferation, GM-CSF activates a fully

20 migrating phenotype. (Bussolino, et al., *J. Clin. Invest.*, 87:986 (1991).

Accordingly, it would be desirable to have methods for modulating vascularization in a mammal and especially a human patient. It would be particularly desirable to have methods that increase EPC mobilization and neovascularization (formation of new blood vessels) in the patient that do not

25 require isolation of EPC cells.

#### SUMMARY OF THE INVENTION

The present invention generally relates to methods for modulating vascularization in a mammal. In one aspect, the invention provides methods

30 for increasing vascularization that includes administering to the mammal an effective amount of a vascularization modulating agent, such as granulocyte macrophage-colony stimulating factor (GM-CSF), VEGF, Steel factor (SLF,

also known as Stem cell factor (SCF)), stromal cell-derived factor (SDF-1), granulocyte-colony stimulating factor (G-CSF), HGF, Angiopoietin-1, Angiopoietin-2, M-CSF, b-FGF, and FLT-3 ligand, and effective fragment thereof, or DNA coding for such vascularization modulating agents. Such materials have sometimes previously been described as "hematopoietic factors," and/or "hematopoietic proteins." Disclosure relating to these and other hematopoietic factors can be found in Kim, C.H. and Broxmeyer, H.E. (1998) *Blood*, 91:100; Turner, M.L. and Sweetenham, J.W., *Br. J. Haematol.* (1996) 94:592; Aiuti, A. et al. (1997) *J. Exp. Med.* 185:111; Bleul, C. et al. (1996) *J. Exp. Med.* 184:1101; Sudo, Y. et al. (1997) *Blood*, 89: 3166; as well as references disclosed therein. Prior to the present invention, it was not known that GM-CSF or other hematopoietic factors could potentiate endothelial progenitor cells, or modulate neovascularization as described herein.

Alternatively, instead of the proteins themselves or effective fragments thereof, the DNA coding for the vascularization modulating agents can be administered to the site where neovascularization is desired, as further discussed below. The invention also relates to methods for treating or detecting damaged blood vessels in the mammal. The invention has many uses including preventing or reducing the severity of blood vessel damage associated with ischemia or related conditions.

We have now discovered that hematopoietic factors such as granulocyte-macrophage colony-stimulating factor (GM-CSF), modulate endothelial progenitor cell (EPC) mobilization and neovascularization (blood vessel formation). In particular, we have found that GM-CSF and other hematopoietic factors increase EPC mobilization and enhances neovascularization. This observation was surprising and unexpected in light of prior reports addressing GM-CSF activity in vitro and in vivo. Accordingly, this invention provides methods for using GM-CSF to promote EPC mobilization and to enhance neovascularization, especially in tissues in need of EPC mobilization and/or neovascularization.

In one aspect, the present invention provides a method for inducing neovascularization in a mammal. By the term "induction" is meant at least enhancing EPC mobilization and also preferably facilitating formation of new blood vessels in the mammal. EPC mobilization is understood to mean a

significant increase in the frequency and differentiation of EPCs as determined by assays disclosed herein. In one embodiment, the method includes administering to the mammal an effective amount of a vascularization modulating factor such as granulocyte macrophage-colony stimulating factor (GM-CSF), that is preferably sufficient to induce the neovascularization in the mammal. Preferably, that amount of GM-CSF is also capable of modulating and particularly increasing frequency of EPCs in the mammal. A variety of methods for detecting and quantifying neovascularization, EPC frequency, the effectiveness of vascularization modulating agents, and other parameters of blood vessel growth are discussed below and in the examples.

In a particular embodiment of the method, the enhancement in EPC mobilization and particularly the increase in frequency of the EPCs is at least about 20% and preferably from between 50% to 500% as determined by a standard EPC isolation assay. That assay generally detects and quantifies EPC enrichment and is described in detail below.

In another particular embodiment of the method, the amount of administered modulating agent is sufficient to enhance EPC mobilization and especially to increase EPC differentiation in the mammal. Methods for detecting and quantifying EPC differentiation include those specific methods described below. Preferably, the increase in EPC differentiation is at least about 20%, preferably between from about 100% to 1000%, more preferably between from about 200% to 800% as determined by a standard EPC culture assay discussed below. More preferably, that amount of administered modulating agent is additionally sufficient to increase EPC differentiation by about the stated percent amounts following tissue ischemia as determined in a standard hindlimb ischemia assay as discussed below.

In another particular embodiment of the method, the amount of vascularization modulating agent administered to the mammal is sufficient to increase blood vessel size in the mammal. Methods for determining parameters of blood vessel size, e.g., length and circumference, are known in the field and are discussed below. Preferably, the amount of administered modulating agent is sufficient to increase blood vessel length by at least about

5%, more preferably between from about 10% to 50%, even more preferably about 20%, as determined by a standard blood vessel length assay discussed below. Preferably, the amount of modulating agent administered to the mammal is also sufficient to increase blood vessel circumference or diameter by the stated percent amounts as determined by a standard blood vessel diameter assay. As will be discussed below, it will often be preferred to detect and quantify changes in blood vessel size using a standard cornea micropocket assay, although other suitable assays can be used as needed.

In another particular embodiment of the method, the amount of administered vascularization modulating agent is sufficient to increase neovascularization by at least about 5%, preferably from between about 50% to 300%, and more preferably from between about 100% to 200% as determined by the standard cornea micropocket assay. Methods for performing that assay are known in the field and include those specific methods described below. Additionally, preferred amounts of GM-CSF are sufficient to improve ischemic hindlimb blood pressure by at least about 5%, preferably between from about 10% to 50% as determined by standard methods for measuring the blood pressure of desired vessels. More specific methods for measuring blood pressure particularly with new or damaged vessels include techniques optimized to quantify vessel pressure in the mouse hindlimb assay discussed below.

In another particular embodiment of the method, the amount of administered vascularization modulating agent is sufficient to increase EPC bone marrow (BM) derived EPC incorporation into foci by at least about 20% as determined by a standard murine BM transplantation model. Preferably, the increase is between from about 50% to 400%, more preferably between from about 100% to 300% as determined by that standard model. More specific methods for determining the increase in EPC incorporation into foci are found in the discussion and Examples which follow.

The methods of this invention are suitable for modulating and especially inducing neovascularization in a variety of animals including mammals. The term "mammal" is used herein to refer to a warm blooded

animal such as a rodent, rabbit, or a primate and especially a human patient. Specific rodents and primates of interest include those animals representing accepted models of human disease including the mouse, rat, rabbit, and monkey. Particular human patients of interest include those which have, are  
5 suspected of having, or will include ischemic tissue. That ischemic tissue can arise by nearly any means including a surgical manipulation or a medical condition. Ischemic tissue is often associated with an ischemic vascular disease such as those specific conditions and diseases discussed below.

As will become more apparent from the discussion and Examples  
10 which follow, methods of this invention are highly compatible and can be used in combination with established or experimental methods for modulating neovascularization. In one embodiment, the invention includes methods for modulating and particularly inducing neovascularization in a mammal in which an effective amount of vascularization modulating agent is co-administered  
15 with an amount of at least one angiogenic protein. In many settings, it is believed that co-administration of the vascularization modulating agent and the angiogenic protein can positively impact neovascularization in the mammal, e.g., by providing additive or synergistic effects. A preferred angiogenic protein is a recognized endothelial cell mitogen such as those specific proteins  
20 discussed below. Methods for co-administering the vascularization modulating agent and the angiogenic protein are described below and will generally vary according to intended use.

The present invention also provides methods for preventing or reducing the severity of blood vessel damage in a mammal such as a human patient in  
25 need of such treatment. In one embodiment, the method includes administering to the mammal an effective amount of vascularization modulating agent such as GM-CSF. At about the same time or subsequent to that administration, the mammal is exposed to conditions conducive to damaging the blood vessels. Alternatively, administration of the  
30 vascularization modulating agent can occur after exposure to the conditions to reduce or block damage to the blood vessels. As discussed, many conditions are known to induce ischemic tissue in mammals which conditions can be particularly conducive to damaging blood vessels, e.g, invasive manipulations

such as surgery, grafting, or angioplasty; infection or ischemia. Additional conditions and methods for administering the vascularization modulating agent are discussed below.

Preferred amounts of the vascularization modulating agent to use in the methods are sufficient to prevent or reduce the severity of the blood vessel damage in the mammal. Particular amounts of GM-CSF have already been mentioned above and include administration of an effective amount of GM-CSF sufficient to induce neovascularization in the mammal. Illustrative methods for quantifying an effective amount of vascularization modulating agents are discussed throughout this disclosure including the discussion and Examples which follow.

The present invention also provides methods for treating ischemic tissue and especially injured blood vessels in that tissue. Preferably, the method is conducted with a mammal and especially a human patient in need of such treatment. In one embodiment, the method includes as least one and preferably all of the following steps:

- a) isolating endothelial progenitor cells (EPCs) from the mammal,
- b) contacting the isolated EPCs with an effective amount of at least one factor sufficient to induce proliferation of the EPCs; and
- c) administering the proliferated EPCs to the mammal in an amount sufficient to treat the injured blood vessel.

In a particular embodiment of the method, the factor is an angiogenic protein including those cytokines known to induce EPC proliferation especially *in vitro*. Illustrative factors and markers for detecting EPCs are discussed below. In one embodiment of the method, the blood vessel (or more than one blood vessel) can be injured by nearly any known means including trauma or an invasive manipulation such as implementation of balloon angioplasty or deployment of a stent or catheter. A particular stent is an endovascular stent. Alternatively, the vascular injury can be organic and derived from a pre-existing or on-going medical condition.

In another particular embodiment of the method, the vascularization

modulating agent is administered to the mammal and especially the human patient alone or in combination (co-administered) with at least one angiogenic protein (or effective fragment thereof) such as those discussed below.

Additionally provided by this invention are methods for detecting  
5 presence of tissue damage in a mammal and especially a human patient. In one embodiment, the method includes contacting the mammal with a detectably-labeled population of EPCs; and detecting the detectably-labeled cells at or near the site of the tissue damage in the mammal. In this example, the EPCs can be harvested and optionally monitored or expanded *in vitro* by nearly any  
10 acceptable route including those specific methods discussed herein. The EPCs can be administered to the mammal by one or a combination of different approaches with intravenous injection being a preferred route for most applications. Methods for detectably-labeling cells are known in the field and include immunological or radioactive tagging as well as specific recombinant  
15 methods disclosed below.

In a particular embodiment of the method, the detectably-labeled EPCs can be used to "home-in" to a site of vascular damage, thereby providing a minimally invasive means of visualizing that site even when it is quite small. The detectably-labeled EPCs can be visualized by a variety of methods well-  
20 known in this field including those using tomography, magnetic resonance imaging, or related approaches.

In another embodiment of the method, the tissue damage is facilitated by ischemia, particularly an ischemic vascular disease such as those specifically mentioned below.

Also provided by this invention are methods for modulating the mobilization of EPCs which methods include administering to the mammal an effective amount of at least one hematopoietic factor. Preferred are methods that enhance EPC mobilization as determined by any suitable assay disclosed herein. For example, in a particular embodiment of the method, the  
30 enhancement in EPC mobilization and particularly the increase in frequency of the EPCs is at least about 20% and preferably from between 50% to 500% as determined by a standard EPC isolation assay.



In another particular embodiment of the method, the amount of administered hematopoietic factor is sufficient to enhance EPC mobilization and especially to increase EPC differentiation in the mammal. Methods for detecting and quantifying EPC differentiation include those specific methods described below. Preferably, the increase in EPC differentiation is at least about 20%, preferably between from about 100% to 1000%, more preferably between from about 200% to 800% as determined by a standard EPC culture assay discussed below. More preferably, that amount of administered hematopoietic factor is additionally sufficient to increase EPC differentiation by about the stated percent amounts following tissue ischemia as determined in a standard hindlimb ischemia assay as discussed below.

As discussed, it has been found that EPC mobilization facilitates significant induction of neovascularization in mammals. Thus, methods that modulate EPC mobilization and particularly enhance same can be used to induce neovascularization in the mammal and especially a human patient in need of such treatment. Methods of this invention which facilitate EPC mobilization including those employing at least one hematopoietic factor which use can be alone or in combination with other methods disclosed herein including those in which an effective amount of vascularization modulating agent is administered to the mammal alone or in combination (co-administered) with at least one angiogenic protein.

In particular, the invention provides methods for inducing neovascularization in a mammal and especially a human patient in need of such treatment which methods include administering to the mammal an effective amount of at least one vascularization modulating agent, preferably one vascularization modulating agent, which amount is sufficient to induce neovascularization in the mammal. That neovascularization can be detected and quantified if desired by the standard assays disclosed herein including the mouse cornea micropocket assay and blood vessel size assays. Preferred methods will enhance neovascularization in the mammal by the stated percent ranges discussed previously.

In one embodiment of the method, the effective amount of the

vascularization modulating agent (s) is co-administered in combination with at least one angiogenic protein, preferably one angiogenic protein. The vascularization modulating agent can be administered to the mammal and especially a human patient in need of such treatment in conjunction with, subsequent to, or following administration of the angiogenic or other protein.

The invention also provides a pharmaceutical product that is preferably formulated to modulate and especially to induce neovascularization in a mammal. In a preferred embodiment, the product is provided sterile and optionally includes an effective amount of GM-CSF and optionally at least one angiogenic protein. In a particular embodiment, the product includes isolated endothelial progenitor cells (EPCs) in a formulation that is preferably physiologically acceptable to a mammal and particularly a human patient in need of the EPCs. Alternatively, the product can include a nucleic acid that encodes the GM-CSF and/or the angiogenic protein.

Also provided by this invention are kits preferably formulated for *in vivo* and particularly systemic introduction of isolated EPCs. In one embodiment, the kit includes isolated EPCs and optionally at least one angiogenic protein or nucleic acid encoding same. Preferred is a kit that optionally includes a pharmacologically acceptable carrier solution, nucleic acid or mitogen, means for delivering the EPCs and directions for using the kit. Acceptable means for delivering the EPCs are known in the field and include effective delivery by stent, catheter, syringe or related means.

Other aspects of the invention are disclosed *infra*.

## BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A-D are representations of photomicrographs showing neovascularization following GM-CSF and VEGF-1 treatment in control (Figs. 1A, 1C) and treated (Figs. 1B and 1D) mice in a cornea micropocket assay.

Figures 2A-B are graphs showing quantitation of increases in vessel length (2A) and vessel angle (2B) observed in the cornea micropocket assay.

Figures 3A-C are graphs showing EPC frequency (3A), EPC differentiation (3B), blood pressure and capillary density (3C) following GM-CSF treatment in the rabbit hindlimb ischemia assay.

5

Figures 4A-4J are representations of photomicrographs showing that EPCs can home and incorporate into foci of neovascularization. (4A) cultured murine cells, (4B-D) homing of Sca-1<sup>+</sup> cells administered to the mouse, (4E-G) immunostaining of rabbit hindlimb muscle showing accumulation and  
10 colonization of EPCs, (4H-J) colonized TBM<sup>+</sup> cells establishing new vessels.

Figures 5A-B are graphs showing EPC kinetics in relation to development of hindlimb ischemia.

15

Figures 5C-F are representations of photomicrographs showing results of the mouse cornea micropocket assay with hindlimb ischemia. (5C-D) slit-lamp biomicroscopy, (5E-F) demonstration of neovascularization.

20

Figures 5G-H are graphs illustrating quantitation of vessel length and circumferential distribution of neovascularization.

25

Figures 6D-G are representations of photomicrographs showing the GM-CSF induced effects described in Figures 6A-C. (6D, E) slit-lamp biomicroscopy, (6F, G) fluorescent photomicrographs.

30

Figures 6H and 6I are graphs showing measurements of vessel length (6H) and vessel circumference (6I) taken from the experiment shown in Figures 6D-G.

Figures 7A-C are graphs showing that detectably-labeled bone-marrow derived EPCs contribute to corneal neovascularization. (7A) corneal

neovascularization in mice with hindlimb ischemia, (7B) rabbits pre-treated with GM-CSF, (7C) beta-galactosidase activity in GM-CSF control group.

#### DETAILED DESCRIPTION OF THE INVENTION

5 As discussed, the present invention provides, in one aspect, methods for inducing neovascularization in a human patient that include administering to the patient an effective amount of GM-CSF or an effective fragment thereof. As also discussed, that GM-CSF can be administered to the human patient alone or in combination (co-administered) with one or more of: at least one  
10 vascularization modulating agent, preferably one of such factors; at least one angiogenic protein, preferably one angiogenic protein; or an effective fragment thereof. Also provided are methods for enhancing EPC mobilization which methods include administration of an effective amount of at least one vascularization modulating agent, preferably one of such factors. Further  
15 provided are methods for treating or detecting damaged blood vessels in the human patient. The invention has a wide spectrum of uses including preventing or reducing the severity of blood vessel damage in the patient.

The invention particularly provides methods for inducing angiogenesis in ischemic tissue of a patient in need such treatment. In this embodiment, the  
20 methods generally include administering to the patient an effective amount of GM-CSF or other vascularization modulating agent disclosed herein. Administration of the GM-CSF (or co-administration with other another protein or proteins) can be as needed and may be implemented prior to, during or after formation of the ischemic tissue. Additionally, the GM-CSF can be  
25 administered as the sole active compound or it can be co-administered with at least one and preferably one angiogenic protein or other suitable protein or fragment as provided herein.

Administration of an effective amount GM-CSF or other  
30 vascularization modulating agent disclosed herein in accord with any of the methods disclosed herein can be implemented by one or a combination of different strategies including administering a DNA encoding same.

As discussed, methods of this invention have a wide spectrum of uses especially in a human patient, e.g., use in the prevention or treatment of at least one of trauma, graft rejection, cerebrovascular ischemia, renal ischemia, pulmonary ischemia, ischemia related to infection, limb ischemia, ischemic cardiomyopathy, cerebrovascular ischemia, and myocardial ischemia.

5      Impacted tissue can be associated with nearly any physiological system in the patient including the circulatory system or the central nervous system, e.g., a limb, graft (e.g., muscle or nerve graft), or organ (e.g., heart, brain, kidney and lung). The ischemia may especially adversely impact heart or brain tissue as

10     often occurs in cardiovascular disease or stroke, respectively.

In embodiments in which an effective amount of the vascularization modulating agent is administered to a mammal and especially a human patient to prevent or reduce the severity of a vascular condition and particularly ischemia, the vascularization modulating agent will preferably be administered

15     at least about 12 hours, preferably between from about 24 hours to 1 week up to about 10 days prior to exposure to conditions conducive to damaging blood vessels. If desired, the method can further include administering the vascularization modulating agent to the mammal following exposure to the conditions conducive to damaging the blood vessels. As discussed, the

20     vascularization modulating agent can be administered alone or in combination with at least one angiogenic protein preferably one of such proteins.

Related methods for preventing or reducing the severity of the vascular condition can be employed which methods include administering alone or in combination (co-administration) with the GM-CSF one or more of: at least one

25     hematopoietic factor, preferably one of such factors; or at least one angiogenic protein, preferably one of such proteins. Preferred methods of administration are disclosed herein.

Vessel injury is known to be facilitated by one or a combination of different tissue insults. For example, vessel injury often results from tissue

30     trauma, surgery, e.g., balloon angioplasty and use of related devices (e.g., directional atherectomy, rotational atherectomy, laser angioplasty, transluminal extraction, pulse spray thrombolysis); and deployment of an endovascular stent

or a vascular graft.

Specific EPCs in accord with this invention will be preferably associated with cell markers that can be detected by conventional

- 5 immunological or related strategies. Preferred are EPCs having at least one of the following markers: CD34<sup>+</sup>, flk-1<sup>+</sup> or tie-2<sup>+</sup>. Methods for detecting EPCs with these markers are discussed in the Examples below.

- 10 As discussed above and in the Examples following, we have discovered means to promote angiogenesis and reendothelialize denuded blood vessels in mammals. These methods involve the use of vascularization modulating agent to mobilize endothelial cell (EC) progenitors. In accordance with the present invention, GM-CSF and other vascularization modulating agents can be used in a method for enhancing angiogenesis in a selected patient having an
- 15 ischemic tissue i.e., a tissue having a deficiency in blood as the result of an ischemic disease such as cerebrovascular ischemia, renal ischemia, pulmonary ischemia, limb ischemia, ischemic cardiomyopathy and myocardial ischemia.

- Additionally, in another embodiment, the vascularization modulating agent, alone or in combination with at least one other factor disclosed herein
- 20 can be used to induce reendothelialization of an injured blood vessel, and thus reduce restenosis by indirectly inhibiting smooth muscle cell proliferation.

- In one preferred embodiment, the vascularization modulating agent, alone or in combination with at least one other factor disclosed herein can be used to prepare a patient for angiogenesis. Some patient populations, typically
- 25 elderly patients, may have either a limited number of ECs or a limited number of functional ECs. Thus, if one desires to promote angiogenesis, for example, to stimulate vascularization by using a potent angiogenesis promotor such as VEGF-1, such vascularization can be limited by the lack of EPCs. However, by administering e.g., GM-CSF at a time before administration of the
- 30 angiogenesis promotor sufficient to allow mobilization of the ECs, one can potentiate the vascularization in those patients. Preferably, GM-CSF is administered about one week prior to treatment with the angiogenesis promotor.

The term "GM-CSF" as used herein shall be understood to refer to a natural or recombinantly prepared protein having substantial identity to an amino acid sequence of human GM-CSF as disclosed, for example, in published international application WO 86/00639, which is incorporated herein by reference. Recombinant human GM-CSF is hereinafter also referred to as "hGM-CSF."

Human GM-CSF (hGM-CSF) has been isolated and cloned, see published International Application No. PCT/EP 85/00326, filed Jul. 4, 1985 (published as WO 86/00639).

10 *E. coli* derived, non-glycosylated rhGM-CSF can be obtained by the methods described in publication of the International Application No. PCT/EP 85/00326, wherein two native GM-CSFs differing in a single amino acid are described.

15 The natural GM-CSF proteins used in the invention may be modified by changing the amino acid sequence thereof. For example, from 1 to 5 amino acids in their sequences may be changed, or their sequences may be lengthened, without changing the fundamental character thereof and provide modified proteins which are the full functional equivalents of the native proteins. Such functional equivalents may also be used in practicing the present invention. A GM-CSF differing by a single amino acid from the common native sequence is disclosed in U.S. Pat. No. 5,229,496 and has been produced in glycosylated form in yeast, and has been clinically demonstrated to be a biological equivalent of native GM-CSF, such modified form known as GM-CSF (Leu-23).

25 GM-CSF is commercially and clinically available as an analog polypeptide (Leu<sup>23</sup>) under the trademark LEUKINE® (Immunex Corporation).

The generic name for recombinant human Leu<sup>23</sup> GM-CSF analog protein expressed in yeast is Sargramostim. Cloning and expression of native sequence human GM-CSF was described in *Cantrell et al., Proc Natl. Acad. Sci. U.S.A. 82:6250(1985)*.

30 The natural or recombinantly prepared proteins, and their functional

equivalents used in the method of the invention are preferably purified and substantially cell-free, which may be accomplished by known procedures.

Additional protein and nucleic sequences relating to the factors disclosed herein including GM-CSF can be obtained through the National  
5 Center for Biotechnology Information (NCBI)- Genetic Sequence Data Bank (Genbank). In particular, sequence listings can be obtained from Genbank at the National Library of Medicine, 38A, 8N05, Rockville Pike, Bethesda, MD 20894. Genbank is also available on the internet at  
<http://www.ncbi.nlm.nih.gov>. See generally Benson, D.A. et al. (1997) *Nucl.*  
10 *Acids. Res.* 25: 1 for a description of Genbank. Protein and nucleic sequences not specifically referenced can be found in Genbank or other sources disclosed herein.

In accord with the methods of this invention, GM-CSF can be  
15 administered to a mammal and particularly a human patient in need of such treatment. As an illustration, GM-CSF as well as therapeutic compositions including same are preferably administered parenterally. More specific examples of parenteral administration include subcutaneous, intravenous, intra-arterial, intramuscular, and intraperitoneal, with subcutaneous being preferred.

20 In embodiments of this invention in which parenteral administration is selected, the GM-CSF will generally be formulated in a unit dosage injectable form (solution, suspension, emulsion), preferably in a pharmaceutically acceptable carrier medium that is inherently non-toxic and non-therapeutic. Examples of such vehicles include without limitation saline, Ringer's solution,  
25 dextrose solution, mannitol and normal serum albumin. Neutral buffered saline or saline mixed with serum albumin are exemplary appropriate vehicles. Non-aqueous vehicles such as fixed oils and ethyl oleate may also be used. Additional additives include substances to enhance isotonicity and chemical stability, e.g., buffers, preservatives and surfactants, such as Polysorbate 80.  
30 The preparation of parenterally acceptable protein solutions of proper pH, isotonicity, stability, etc., is within the skill of the art.

Preferably, the product is formulated by known procedures as a



lyophilizate using appropriate excipient solutions (e.g., sucrose) as a diluent.

Preferred *in vivo* dosages the vascularization modulating agents are from about 1  $\mu\text{g/kg/day}$  to about 100 $\mu\text{g/kg/day}$ . Use of more specific dosages will be guided by parameters well-known to those in this field such as the specific condition to be treated and the general health of the subject. See also U.S. Patent No. 5,578,301 for additional methods of administering GM-CSF. Preferred *in vivo* dosages for the hematopoietic proteins and angiogenic proteins disclosed herein will be within the same or similar range as for GM-CSF.

As discussed, for some applications it will be useful to augment the vascularization modulating agent administration by co-administering one or more of: at least one hematopoietic protein, at least one angiogenic protein; or an effective fragment thereof. This approach may be especially desirable where an increase (boost) in angiogenesis is needed. For example, in one embodiment, at least one angiogenic protein and preferably one of same will be administered to the patient in conjunction with, subsequent to, or prior to the administration of the GM-CSF. The angiogenic protein can be administered directly, e.g., intra-arterially, intramuscularly, or intravenously, or nucleic acid encoding the mitogen may be used. See, Baffour, et al., *supra* (bFGF); Pu, et al, *Circulation*, 88:208-215 (1993) (aFGF); Yanagisawa-Miwa, et al., *supra* (bFGF); Ferrara, et al., *Biochem. Biophys. Res. Commun.*, 161:851-855 (1989) (VEGF-1); (Takeshita, et al., *Circulation*, 90:228-234 (1994); Takeshita, et al., *Laboratory*, 75:487-502 (1996); Tsusumi, et al., *Circulation*, 94 (12):3281-3290 (1996)).

As another illustration, at least one hematopoietic protein and preferably one of such proteins can be administered to the human patient in need of such treatment in conjunction with, subsequent to, or prior to the administration of the GM-CSF. As discussed, at least one angiogenic protein can also be co-administered with the GM-CSF and hematopoietic protein. Methods for administering the hematopoietic protein will generally follow those discussed for administering the GM-CSF although other modes of administration may be suitable for some purposes.

It will be understood that the term "co-administration" is meant to describe preferred administration of at least two proteins disclosed herein to the mammal, ie., administration of one protein in conjunction with, subsequent to, or prior to administration of the other protein.

5 In embodiments in which co-administration of a DNA encoding and angiogenic or hematopoietic protein is desired, the nucleic acid encoding same can be administered to a blood vessel perfusing the ischemic tissue via a catheter, for example, a hydrogel catheter, as described by U.S. Patent No 5,652,225, the disclosure of which is herein incorporated by reference. The  
10 nucleic acid also can be delivered by injection directly into the ischemic tissue using the method described in PCT WO 97/14307.

As used herein the term "angiogenic protein" or related term such as "angiogenesis protein" means any protein, polypeptide, mutein or portion that is capable of, directly or indirectly, inducing blood vessel growth. Such  
15 proteins include, for example, acidic and basic fibroblast growth factors (aFGF and bFGF), vascular endothelial growth factor (VEGF-1), VEGF165, epidermal growth factor (EGF), transforming growth factor  $\alpha$  and  $\beta$  (TGF- $\alpha$  and TGF- $\beta$ ), platelet-derived endothelial growth factor (PD-ECGF), platelet-derived growth factor (PDGF), tumor necrosis factor  $\alpha$  (TNF- $\alpha$ ), hepatocyte  
20 growth factor (HGF), insulin like growth factor (IGF), erythropoietin, colony stimulating factor (CSF), macrophage-CSF (M-CSF), granulocyte/macrophage CSF (GM-CSF), angiopoietin-1 (Ang1) and nitric oxidesynthase (NOS). See, Klagsbrun, et al., *Annu. Rev. Physiol.*, 53:217-239 (1991); Folkman, et al., *J. Biol. Chem.*, 267:10931-10934 (1992) and Symes, et al., *Current Opinion in*  
25 *Lipidology*, 5:305-312 (1994). Muteins or fragments of a mitogen may be used as long as they induce or promote blood vessel growth.

Preferred angiogenic proteins include vascular endothelial growth factors. One of the first of these was termed VEGF, now called VEGF-1, exists in several different isoforms that are produced by alternative splicing  
30 from a single gene containing eight exons (Tischer, et al., *J. Biol. Chem.*, 806, 11947-11954 (1991), Ferrara, *Trends Cardio. Med.*, 3, 244-250 (1993), Polterak, et al., *J. Biol. Chem.*, 272, 7151-7158 (1997)). Human VEGF

isoforms consists of monomers of 121 (U.S. Patent No. 5,219,739), 145, 165 (U.S. Patent No. 5,332,671), 189 (U.S. Patent No. 5,240,848) and 206 amino acids, each capable of making an active homodimer (Houck, et al., *Mol. Endocrinol.*, 8, 1806-1814 (1991)).

- 5 Other vascular endothelial growth factors include VEGF-B and VEGF-C (Joukou, et al., *J. of Cell. Phys.* 173:211-215 (1997), VEGF-2 (WO 96/39515), and VEGF-3 (WO 96/39421).

- Preferably, the angiogenic protein contains a secretory signal sequence that facilitates secretion of the protein. Proteins having native signal  
10 sequences, e.g., VEGF-1, are preferred. Proteins that do not have native signal sequences, e.g., bFGF, can be modified to contain such sequences using routine genetic manipulation techniques. See, Nabel et al., *Nature*, 362:844 (1993).

- Reference herein to a "vascularization modulating agent",  
"hematopoietic factor" or related term, e.g., "hematopoietic protein" is used  
15 herein to denote recognized factors that increase mobilization of hematopoietic progenitor cells (HPC). Preferred hematopoietic factors include granulocyte-macrophage colony-stimulating factor (GM-CSF), VEGF, Steel factor (SLF, also known as Stem cell factor (SCF)), stromal cell-derived factor (SDF-1), granulocyte-colony stimulating factor (G-CSF), HGF, Angiopoietin-1,  
20 Angiopoietin-2, M-CSF, b-FGF, and FLT-3 ligand. Disclosure relating to these and other hematopoietic factors can be found in Kim, C.H. and Broxmeyer, H.E. (1998) *Blood*, 91: 100; Turner, M.L. and Sweetenham, J.W., *Br. J. Haematol.* (1996) 94: 592; Aiuuti, A. et al. (1997) *J. Exp. Med.* 185: 111; Bleul, C. et al. (1996) *J. Exp. Med.* 184: 1101; Sudo, Y. et al. (1997) *Blood*,  
25 89: 3166; as well as references disclosed therein.

- The nucleotide sequence of numerous angiogenic proteins, are readily available through a number of computer databases, for example, GenBank, EMBL and Swiss-Prot. Using this information, a DNA segment encoding the desired may be chemically synthesized or, alternatively, such a DNA segment  
30 may be obtained using routine procedures in the art, e.g. PCR amplification.

In certain situations, it may be desirable to use nucleic acids encoding

two or more different proteins in order optimize therapeutic outcome. For example, DNA encoding two proteins, e.g., VEGF-1 and bFGF, can be used, and provides an improvement over the use of bFGF alone. Or an angiogenic factor can be combined with other genes or their encoded gene products to enhance the activity of targeted cells, while simultaneously inducing angiogenesis, including, for example, nitric oxide synthase, L-arginine, fibronectin, urokinase, plasminogen activator and heparin.

The term "effective amount" means a sufficient amount of a compound, e.g. protein or nucleic acid delivered to produce an adequate level of the subject protein (e.g., GM-CSF, vascularization modulating agent, hematopoietic protein, angiogenic protein) i.e., levels capable of inducing endothelial cell growth and/or inducing angiogenesis as determined by standard assays disclosed throughout this application. Thus, the important aspect is the level of protein expressed. Accordingly, one can use multiple transcripts or one can have the gene under the control of a promoter that will result in high levels of expression. In an alternative embodiment, the gene would be under the control of a factor that results in extremely high levels of expression, e.g., *tat* and the corresponding *tar* element.

To simplify the manipulation and handling of the nucleic acid encoding the protein, the nucleic acid is preferably inserted into a cassette where it is operably linked to a promoter. The promoter must be capable of driving expression of the protein in cells of the desired target tissue. The selection of appropriate promoters can readily be accomplished. Preferably, one would use a high expression promoter. An example of a suitable promoter is the 763-base-pair cytomegalovirus (CMV) promoter. The Rous sarcoma virus (RSV) (Davis, et al., *Hum Gene Ther* 4:151 (1993)) and MMT promoters may also be used. Certain proteins can be expressed using their native promoter. Other elements that can enhance expression can also be included such as an enhancer or a system that results in high levels of expression such as a *tat* gene and *tar* element. This cassette can then be inserted into a vector, e.g., a plasmid vector such as pUC118, pBR322, or other known plasmid vectors, that includes, for example, an *E. coli* origin of replication. See, Sambrook, et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory press, (1989).

The plasmid vector may also include a selectable marker such as the  $\beta$ -lactamase gene for ampicillin resistance, provided that the marker polypeptide does not adversely effect the metabolism of the organism being treated. The cassette can also be bound to a nucleic acid binding moiety in a synthetic delivery system, such as the system disclosed in WO 95/22618.

Particular methods of the present invention may be used to treat blood vessel injuries that result in denuding of the endothelial lining of the vessel wall. For example, primary angioplasty is becoming widely used for the treatment of acute myocardial infarction. In addition, endovascular stents are becoming widely used as an adjunct to balloon angioplasty. Stents are useful for rescuing a sub-optimal primary result as well as for diminishing restenosis. To date, however, the liability of the endovascular prosthesis has been its susceptibility to thrombotic occlusion in approximately 3% of patients with arteries 3.3 mm or larger. If patients undergo stent deployment in arteries smaller than this the incidence of sub-acute thrombosis is even higher. Sub-acute thrombosis is currently prevented only by the aggressive use of anticoagulation. The combination of vascular intervention and intense anticoagulation creates significant risks with regard to peripheral vascular trauma at the time of the stent/angioplasty procedure. Acceleration of reendothelialization by administration of GM-CSF alone or in combination with other factors disclosed herein to a patient prior to undergoing angioplasty and/or stent deployment can stabilize an unstable plaque and prevent re-occlusion. In this example, GM-CSF is preferably administered about 1 week prior to the denuding of the vessel wall.

The methods of the present invention may be used in conjunction a DNA encoding an endothelial cell mitogen in accordance with the method for the treatment of vascular injury disclosed in PCT/US96/15813.

As used herein the term "endothelial cell mitogen" means any protein, polypeptide, muten or portion that is capable of inducing endothelial cell growth. Such proteins include, for example, vascular endothelial growth factor (VEGF-1), acidic fibroblast growth factor (aFGF), basic fibroblast growth factor (bFGF), hepatocyte growth factor (scatter factor), and colony stimulating

factor (CSF). VEGF-1 is preferred.

In addition, the methods of the present invention may be used to accelerate the healing of graft tissue, e.g., vascular grafts, by potentiating vascularization.

5           Reference herein to a "standard EPC isolation assay" or other similar phrase means an assay that includes at least one of and preferably all of the following steps:

- a) obtaining a peripheral blood sample from a subject mammal, preferably a rodent and especially a mouse,
- 10       b) separating from the blood sample light-density mononuclear cells,
- c) contacting the separated mononuclear cells with beads that include a sequence capable of specifically binding Sca-1<sup>+</sup> cells and separating same from the mononuclear cells; and
- d) quantitating the Sca-1<sup>+</sup> cells, eg., by counting those cells manually.

15           See the following discussion and Examples for more specific disclosure relating to the standard EPC isolation assay.

By the term "standard EPC culture assay" or related term is meant an assay that includes at least one of and preferably all of the following steps.

- 20       a) isolating Sca-1<sup>+</sup> and Sca-1<sup>-</sup> cells from the peripheral blood of mouse, or TBM<sup>+</sup> and TBM<sup>-</sup> cells from the peripheral blood of a rabbit, and detectably-labelling the cells (Sca-1<sup>+</sup> and TBM<sup>-</sup>), e.g., with Di-I as provided herein,
- 25       b) culturing the cells in a suitable dish or plate in medium for several days and usually for about 4 days,
- c) counting any attached spreading cells in the dish or plate as being Di-I labeled Sca-1<sup>+</sup> or TBM<sup>-</sup> or non-labeled Sca-1<sup>-</sup> or TBM<sup>+</sup>,
- 30       d) and quantitating specific positive cells as being indicative of EPCs.

More specific disclosure relating to the standard EPC culture assay can be found in the discussion and Examples that follow.

35           Reference herein to a "standard hind limb ischemia assay" or related term is meant to denote a conventional assay for inducing hindlimb ischemia in accepted animal models and particularly the mouse or rabbit. Disclosure

relating to conducting the assay can be found in the Examples and Materials and Methods section that follows. See also Couffinhal, T. et al. (1998) *Am. J. Pathol., infra*; and Takeshita, S. et al. (1994) *J. Clinical. Invest.* 93: 662 for more disclosure relating to performing the assay.

5           Reference herein to a "standard blood vessel length assay" or "standard blood vessel diameter assay" generally means exposing a blood vessel of interest in the subject mammal (e.g., mouse or rabbit) and measuring the length or diameter of that vessel by conventional means following inspection of that vessel. Illustrative blood vessels such as certain arteries or veins which can be  
10       measured are provided below.

          The phrase "standard cornea micropocket assay" or related term is used herein in particular reference to a mouse corneal neovascularization assay. The assay generally involves one and preferably all of the following steps.

- a) creating a corneal micropocket in at least one eye of a mouse,  
15       b) adding to the pocket a pellet including an acceptable polymer and at least one angiogenic protein, preferably VEGF-1,  
          c) examining the mouse eye, e.g., by slit-lamp biomicroscopy for vascularization,  
20       typically a few days, e.g., 5 to 6 days following step b),  
          d) marking EC cells in the eye, e.g., with BS-1 lectin; and  
          e) quantitating vascularization and optionally EC cell counts in the eye.

          For more specific disclosure relating to the standard cornea  
25       micropocket assay, see the discussion and Examples which follow. If desired, the assay can include a control as a reference which control will include performing steps a)-e) above, except that step b) will include adding a pellet without the angiogenic protein.

          Reference herein to a "standard murine bone marrow (BM)  
30       transplantation model" or similar phrase is meant at least one and preferably all of the following steps.

- a) obtaining detectably-labeled BM cells from a donor mammal and typically a mouse,
- b) isolating low-density BM mononuclear cells from the mouse,
- 5 c) removing BM cells from a suitable recipient mouse, e.g., by irradiation,
- d) administering the isolated and detectably- labeled BM cells to the recipient mouse,
- e) exposing the recipient mouse to conditions conducive to damaging blood vessels in the mouse, e.g., hindlimb ischemia,
- 10 f) administering an effective amount of GM-CSF to the recipient mouse,
- g) harvesting at least one cornea from the recipient mouse; and
- h) detecting and quantitating any labeled BM cells in the cornea.

- An illustrative detectable-label is beta-galactosidase enzyme activity.
- 15 More specific information relating to the assay can be found in the discussion and Examples which follow.

- Reference herein to an "effective fragment" of vascularization modulating agents such as GM-CSF, a hemopoietic protein, or angiogenic protein means an amino acid sequence that exhibits at least 70%, preferably
- 20 between from about 75% to 95% of the vessel promoting activity of the corresponding full-length protein as determined by at least one standard assay as disclosed herein. Preferred are those assays which detect and preferably quantify EPC mobilization although other standard assays can be used. As an illustration, a preferred effective fragment of GM-CSF will have at least 70%
- 25 and preferably from about 75% to 95% of the vessel promoting activity of full-length human GM-CSF (see the published International Application No. PCT/EP/85/00376 (WO86/00639)) as determined in the standard corneal micropocket assay and especially the standard blood vessel length or diameter assays.

- 30 All documents mentioned herein are incorporated by reference herein in their entirety.

The present invention is further illustrated by the following examples. These examples are provided to aid in the understanding of the invention and



are not construed as a limitation thereof.

### **Example 1- Modulation of EPC kinetics by Cytokine Administration**

Circulating EPCs may constitute a reparative response to injury.

The hypothesis that cytokine-administration may mobilize EPCs and thereby  
5 augment therapeutic neovascularization was investigated as follows.

GM-CSF, which induces proliferation and differentiation of  
hematopoietic progenitor cells (Socinski, et al., *Lancet*, 1988; 1:1194-1198,  
Gianni, et al., *Lancet*, 1989;2:580-584) and cells of myeloid lineage (Clark, et  
10 al., *Science* 1987;236:1229-1237, Sieff, C., *J. Clin. Invest.* 1987;79:1549-  
1557), as well as non-hematopoietic cells including BM stroma cells (Dedhar,  
et al., *Proc. Natl. Acad. Sci USA* 1988;85:9253-9257) and ECs (Bussolini, et  
al., *J. Clin. Invest.*, 1991;87:986-995), was used to promote cytokine-induced  
EPC mobilization. To avoid a direct mitogenic effect on ECs, GM-CSF was  
15 administered for 7 days prior to creating the stimulus for neovascularization.  
De novo vascular formation was initially examined in the mouse cornea pocket  
assay described above. GM-CSF-pretreatment (intraperitoneal [i.p.] rmGM-  
CSF [R&D Systems] 500 ng/day) increased circulating EPCs (221% of  
untreated controls) at day 0, i.e., prior to creation of the cornea micropocket  
20 and insertion of VEGF pellet; correspondingly, neovascularization at day 6  
(Figures 1A-C) was augmented in comparison to control mice (length =  $0.67 \pm$   
 $0.04$  vs  $0.53 \pm 0.04$ ,  $p < 0.05$ ; angle (circumferential degrees occupied by  
neovascularity) =  $155 \pm 13$  vs  $117 \pm 12$ ,  $p < 0.05$ ) (Figures 1B-1D). See also  
Figures 2A and 2B.

25

### **Example 2- Cytokine-induced EPC mobilization Enhances**

Neovascularization of Ischemic Tissues

To determine if cytokine-induced EPC mobilization could enhance  
30 neovascularization of ischemic tissues, we employed the rabbit hindlimb  
ischemia model (Takeshita, et al., *J. Clin. Invest.* 1994;93:662-670). In GM-  
CSF pretreated rabbits (subcutaneous [s.c.] rhGM-CSF;  $50 \mu\text{g/day s.c.}$ ), EPC-  
enriched cell population was increased (189% compared to control animals),

and EPC differentiation was enhanced (421% compared to control) at day 0 of (i.e., prior to) surgery (Figure 3). Morphometric analysis of capillary density disclosed extensive neovascularization induced by GM-CSF pre-treatment compared to control (ischemia, no GM-CSF) group (249 vs 146/mm<sup>2</sup>, p<0.01).

- 5 GM-CSF pre-treatment also markedly improved ischemic limb/normal limb blood pressure ratio (0.71 vs 0.49, p<0.01) (Figures 3A-3C).

### Example 3- EPC Kinetics During Tissue Ischemia.

- 10 To investigate EPC kinetics during tissue ischemia, the frequency and differentiation of EPCs were assessed by EPC isolation from peripheral blood and EPC culture assay. EPC-enriched fractions were isolated from mice as Sca-1 antigen-positive (Sca-1<sup>+</sup>) cells, and from rabbits as the cell population depleted of T-lymphocytes, B-lymphocytes and monocytes (TBM<sup>-</sup>), denoted by the antigen repertoire CD5-/Igμ-/CD11b-.

15

- The frequency of EPC-enriched population marked by Sca-1 in the circulation was 10.7±1.0% in C57/6JBL normal mice. A subset of Sca-1<sup>+</sup> cells plated on rat vitronectin attached and became spindle-shaped within 5 days. Co-cultures of Sca-1<sup>+</sup> and Sca-1 negative (Sca-1<sup>-</sup>) cells were examined after marking Sca-1<sup>+</sup> cells with DiI fluorescence. Sca-1<sup>+</sup> cells developed a spindle-shaped morphology. Mouse adherent cells in co-culture were found to be principally derived from DiI-marked Sca-1<sup>+</sup> cells (65~84%) and showed evidence of EC lineage by reaction with BS-1 lectin and uptake of acLDL<sup>1</sup> (Figure 4A). To determine if Sca-1<sup>+</sup> cells can differentiate into ECs in vivo, a homogeneous population of DiI-marked Sca-1<sup>+</sup> cells, isolated from peripheral blood of the same genetic background, was administered intravenously to mice with hindlimb ischemia (Couffinhal, T., et al. *Am.J.Pathol.* (1998) day after ischemic surgery. DiI-labeled EPC-derived cells were shown to be differentiated in situ into ECs by co-staining for CD31 (PECAM) and were found incorporated into colonies, sprouts, and capillaries (Figures 4A-4D).

30

For the rabbit model, mature HCs were depleted using antibodies to T and B lymphocytes and monocytes, yielding an EPC-enriched (TBM<sup>-</sup>) fraction. The frequency of TBM<sup>-</sup> EPC-enriched population in rabbit peripheral

blood was  $22.0 \pm 1.4\%$ . Differentiation of EPCs was assayed by counting adherent cultured mononuclear blood cells. Adherent cells in EPC culture were found again to be derived principally from DiI-marked TBM<sup>+</sup> cells (71–92%) and showed evidence of EC lineage by positive reaction with BS-1 lectin and uptake of acLDL.

TBM<sup>+</sup> cells were shown to differentiate into ECs in vivo by administration of autologous DiI-marked TBM<sup>+</sup> cells, isolated from 40 ml peripheral blood, to rabbits with unilateral hindlimb ischemia (Takeshita, S., et al. *J.Clin.Invest.* (1994) at 0, 3 and 7 days post-operatively. DiI-labeled EPC-derived cells differentiated in situ into ECs, shown by co-staining for CD31 and incorporation into colonies, sprouts, and capillaries (Figures 4E-4J).

Figures 4A-4D are more particularly explained as follows. The figures provide fluorescent microscopic evidence that EPCs derived from isolated populations of Sca-1<sup>+</sup> cells in mice, and TBM<sup>+</sup> cells in rabbit, can home and incorporate into foci of neovascularization. In particular, in Figure 4A cultured murine cells are shown, double-stained for acLDL-DiI (red) and BS-1 lectin (green) 4 days after EPC culture assay. (Figures 4B-D) Sca-1<sup>+</sup> cells administered to mouse with hindlimb ischemia have homed, differentiated and incorporated into foci of neovascularization in mouse ischemic hindlimb muscles 2 wks after surgery. Figures 4B and 4C document that DiI-labelled Sca-1<sup>+</sup> derived cells (red) co-localize with CD31 (green) indicating that these EPCs have incorporated into CD31-positive vasculature. Arrows indicate cells positive for DiI and CD31 (derived from delivered EPCs), while arrowheads indicate CD31-positive, DiI-negative (autologous ECs). Non-fluorescent, phase contrast photograph in Figure 1d documents vascular foci of EPCs (arrows) are within interstitial sites adjacent to skeletal myocytes.

Figures 4E-G show immunostaining of rabbit ischemic hindlimb muscle 2 wks after ischemia surgery shows accumulation and colonization of EPCs, in this case isolated as TBM<sup>+</sup> cells (red) (Figure 4E); these cells were

marked with DiI and reinjected at day 0, 3 and 7. Figure 4F shows that these cells co-label with CD31, within neovascular foci. DAPI stains cell nuclei (blue) (Figure 1G). (Figures 4H-J). Colonized TBM<sup>+</sup> cells are incorporated into developing sprouts, establishing new capillaries among skeletal myocytes.

5

#### **Example 4- Confirmation of EPC Kinetics During Tissue Ischemia**

EPC kinetics during severe tissue ischemia were assayed for frequency and differentiation. The EPC-enriched population in circulating blood increased following the onset of ischemia, peaking at day 7 post-operatively (day 7 vs day 0:  $17.5 \pm 2.4$  vs  $3.8 \pm 0.6 \times 10^5/\text{ml}$  in mouse [ $p < 0.05$ ],  $11.4 \pm 0.6$  vs  $6.7 \pm 0.3 \times 10^5/\text{ml}$  in rabbit [ $p < 0.05$ ]) (Figures 5A, 6A). EPC assay culture demonstrated dramatic enhancement of EPC differentiation after ischemia, peaking at day 7 (day 7 vs day 0:  $263 \pm 39$  vs  $67 \pm 14 /\text{mm}^2$  in mouse [ $p < 0.05$ ],  $539 \pm 73$  vs  $100 \pm 19$  in rabbit [ $p < 0.05$ ]) (Figures 5B, 6B). Neither the frequency of the EPC-enriched population nor the EPC culture assay showed a significant increase in EPC kinetics in either sham-operated animal model at 7 days following surgery.

Figures 5A and 5B are more specifically explained as follows. The figures show EPC kinetics in relation to development of hindlimb ischemia. (Figure 5A) Following surgery to create ischemic hindlimb, frequency of mouse EPC-enriched population (Sca-1<sup>+</sup>) in circulating blood increases, becoming maximum by day 7 ( $n=5$  mice at each time point). (Figure 5B) Adherent cells in EPC culture are derived principally from DiI-marked Sca-1<sup>+</sup> cells. Assay culture demonstrates enhanced EPC differentiation after surgically induced ischemia with a peak at day 7 ( $n=5$  each time point).

Figures 5C-H show results of the mouse cornea micropocket assay as applied to mice with hindlimb ischemia 7 days after surgery. Slit-lamp biomicroscopy (Figures 5C and 5D) and fluorescent photomicrographs (Figures 5E and 5F) demonstrate that neovascularization in avascular area of

mouse cornea is enhanced by EPC mobilization induced by ischemia, shown with the same magnification. (Figures 5G and 5H) Quantitative analysis of two parameters, vessel length and circumferential distribution of neovascularization, indicates that corneal neovascularization was more profound in animals with hindlimb ischemia (n=7 mice) than in non-ischemic, sham control mice (n=9) (\*=p<0.05).

**Example 5- Analysis of Impact of Enhanced EPC Mobilization on Neovascularization**

To investigate the impact on neovascularization of enhanced EPC mobilization induced by ischemia, the mouse cornea micropocket assay was applied to animals in which hindlimb ischemia had been surgically created 3 days earlier. Slit-lamp (Figures 5C and 6D) and fluorescent (Figures 5E, 6F) photomicrographs documented that neovascularization of avascular mouse cornea was enhanced in animals with hindlimb ischemia compared to non-ischemic sham-operated controls. Measurements of vessel length and circumference showed a significant effect of EPC mobilization on neovascularization in ischemic animals versus sham control mice (length =  $0.67 \pm 0.04$  vs  $0.53 \pm 0.04$  mm,  $p < 0.05$ ; circumference =  $43.3 \pm 3.5$  vs  $32.4 \pm 3.4$  %,  $p < 0.05$ ) (Figures 5G, 5H).

**Example 6- Confirmation of Enhanced Neovascularization with Cytokine-induced EPC Mobilization**

The rabbit model of hindlimb ischemia (Takeshita, S., et al. *J.Clin.Invest.* (1994)) was employed to determine if cytokine-induced EPC mobilization could enhance neovascularization of ischemic tissues. To effect GM-CSF-induced EPC mobilization while avoiding a direct effect on ECs, recombinant human GM-CSF was administered daily for 7 days prior to development of hindlimb ischemia. Such GM-CSF pre-treatment ( $50 \mu\text{g/day}$  s.c.) increased the EPC-enriched population ( $12.5 \pm 0.8$  vs  $6.7 \pm 0.3 \times 10^3/\text{ml}$ ,

- p<0.01) and enhanced EPC differentiation ( $423 \pm 90$  vs  $100 \pm 19$  /mm<sup>2</sup>, p<0.01) at day 0 (day 7 of pre-treatment prior to surgery). By post-operative day 7, the frequency of circulating EPCs and EPC differentiation in GM-CSF-pretreated group exceeded control values ( $20.9 \pm 1.0$  vs  $11.3 \pm 2.5 \times 10^5$ /ml [p<0.05], 813 $\pm$ 54 vs 539 $\pm$ 73 /mm<sup>2</sup> [p<0.01]) respectively (Figures 6A, 6B). Capillary density analysis documented extensive neovascularization induced by GM-CSF pre-treatment ( $249 \pm 18$  vs  $146 \pm 18$  /mm<sup>2</sup> in untreated controls, p<0.01), as well as improved ischemic/normal hindlimb blood pressure ratio ( $0.71 \pm 0.03$  vs  $0.49 \pm 0.03$ , P<0.01) (Figure 6C).
- Figures 6A-I are explained in more detail as follows. The figures show the effect of GM-CSF-induced EPC mobilization on neovascularization in rabbit ischemic hindlimb model. (Figures 6A,B) Following pre-treatment with GM-CSF, circulating EPC-enriched population (TBM) is increased in number compared to control (ischemic, untreated) animals beginning at day 0 (prior to surgery) through day 7 (Figure 6A), as is EPC differentiation in culture (Figure 5B) (n=5 mice at each time point). (Figure 6C) Two weeks after onset of rabbit ischemia, physiological assessment using blood pressure ratio of ischemic to healthy limb indicates significant improvement in rabbits receiving GM-CSF versus control group. Moreover, histologic examination with alkaline phosphatase staining documented increased capillary density in GM-CSF treated rabbits compared to control group (n=9 mice in each group). (\*p<0.01, \*\*p<0.05).

- Slit-lamp biomicroscopy (Figures 6D and 6E) and fluorescent photomicrographs (Figures 6F and 6G, same magnification) show that neovascularization in avascular area of mouse cornea is also enhanced by EPC mobilization induced by GM-CSF pretreatment. (Figures 6H and 6I) Measurements of vessel length and circumference indicate significant effect of EPC mobilization on neovascularization in GM-CSF pretreated (n=6) versus control mice (n=10) (\*p<0.05).

**Example 7-Confirmation of Enhanced Neovascularization Using The Mouse Cornea Micropocket Assay**

5        These results described above were corroborated by assessment of de novo vascularization in the mouse cornea micropocket assay. GM-CSF-pretreated mice (rmGM-CSF, 500ng/day i.p.) developed more extensive corneal neovascularization than control mice (length =  $0.65 \pm 0.05$  vs  $0.53 \pm 0.04$ ,  $p < 0.05$  mm; circumference =  $38.0 \pm 3.5$  vs  $28.3 \pm 2.7$  %,  $p < 0.05$ ) (Figures 6D-6I).

10

**Example 8- Enhanced BM-derived EPC incorporation in the BM Transplantation Model**

15        A murine BM transplantation (BMT) model was employed to establish direct evidence of enhanced BM-derived EPC incorporation into foci of corneal neovascularization in response to ischemia and GM-CSF. Corneas excised 6 days after micropocket implantation and examined by light microscopy demonstrated a statistically significant increase in cells expressing beta-galactosidase in the ischemic limb versus sham group ( $3.5 \pm 0.6$  vs  $10.5 \pm 1.7$ ,  $p < 0.01$ ); the same was true for BMT recipients treated with GM-CSF vs control ( $3.2 \pm 0.3$  vs  $12.4 \pm 1.7$ ,  $p < 0.01$ ) (Figures 7A, 7B). Corneas from control mice (post-BMT) disclosed no cells expressing  $\beta$ -galactosidase. Quantitative chemical detection confirmed a statistically significant increase in  $\beta$ -galactosidase activity among mice receiving GM-CSF vs controls  
20        ( $2.90 \pm 0.30$  vs  $2.11 \pm 0.09 \times 10^3$ ,  $p < 0.05$ ) (Figure 7C).

25

      Figures 7A-C are explained in more detail as follows. The figures illustrate that Bone marrow-derived EPCs contribute to corneal neovascularization. Photomicrographs shown as inserts document incorporation of BM-derived EPCs expressing endothelial-specific Tie-2/lacZ  
30        (blue cells) into foci of corneal neovascularization, both in mice with hindlimb ischemia (Figure 7A), as well as in rabbits pretreated with GM-CSF (Figure 7B). The frequency of incorporated EPCs stained by X-gal was manually

counted under light microscopy. (Figure 7A) Incorporated EPCs were significantly more frequent in mice with hindlimb ischemia vs the sham-operated mice; (Figure 7B) the same was true for rabbits receiving GM-CSF group vs control rabbits (\*= $p<0.01$  for each condition). (Figure 7C)  $\beta$ -galactosidase activity was significantly higher in GM-CSF group than control group. \*\*= $p<0.05$ ).

The development of limb ischemia was observed to induce EPC mobilization, and these EPCs consequently contribute to "vasculogenic" neovascularization. Ledney et al (Ledney, G.D., et al *J.Surg.Res.* (1985) reported that wound trauma causes mobilization of HCs including pluripotent stem or progenitor cells in spleen, BM, and peripheral blood. Because EPCs are derived from BM and EPC mobilization is enhanced during tissue ischemia, circulating EPCs may constitute a reparative response to ischemic injury, controlled by BM via circulating cytokines and soluble receptors and/or adhesive molecules.

The results indicate that GM-CSF exerts a potent stimulatory effect on EPC kinetics and that such cytokine-induced EPC mobilization can enhance neovascularization of severely ischemic tissues as well as de novo vascularization of previously avascular sites. In particular, the Examples show mobilization of EPCs in response to endogenous and exogenous stimuli.

The discussion and Examples above addressed the significance of We investigated the endogenous stimuli, namely tissue ischemia, and exogenous cytokine therapy, specifically granulocyte macrophage-colony stimulating factor (GM-CSF), in the mobilization of EPCs and induction of neovascularization of ischemic tissues. Development of regional ischemia in both mice and rabbits was found to increase the frequency of circulating EPCs. In mice, the impact of ischemia-induced EPC mobilization was shown by enhanced ocular neovascularization following cornea micropocket surgery in animals with hindlimb ischemia compared to non-ischemic controls. In rabbits with hindlimb ischemia, circulating EPCs were further augmented following



GM-CSF pre-treatment, with a corresponding improvement in hindlimb neovascularization. Direct evidence that EPCs which contributed to enhanced corneal neovascularization were specifically mobilized from the bone marrow (BM) in response to ischemia and GM-CSF was documented in mice

- 5 transplanted with BM from transgenic donors expressing  $\beta$ -galactosidase transcriptionally regulated by the endothelial cell (EC) specific Tie-2 promoter. These findings indicate that circulating EPCs are mobilized endogenously in response to tissue ischemia or exogenously by cytokine therapy and thereby augment neovascularization of ischemic tissues.

10

In particular, the concept of EPC mobilization and subsequent neovascularization as disclosed herein and in the co-pending U.S. Provisional Application No. 60/077,262 is believed to represent a potent strategy for the prevention and treatment of a variety of ischemic vascular diseases including

15 those specifically mentioned herein.

General Comments- The following Materials and Methods were used as needed in the Examples above.

#### 1. Isolation of mouse EPC-enriched fraction from peripheral blood

- 20 Peripheral blood samples of mice were obtained from the heart immediately before sacrifice, and separated by Histopaque-1083 (Sigma, St. Louis, MO) density gradient centrifugation at 400g for 20 min. The light-density mononuclear cells were harvested, washed twice with Dulbecco's phosphate buffered saline supplemented with 2mM EDTA (DPBS-E) and
- 25 counted manually. Blood mononuclear cells in each animal were suspended in 500  $\mu$ l of DPBS-E buffer supplemented with 0.5% bovine serum albumin (Sigma) with 50 $\mu$ l of Sca-1 microbeads (Miltenyi Biotec, Auburn, CA) for 15 min at 4°C. After washing cells with buffer, Sca-1 antigen positive (Sca-1<sup>+</sup>) cells were separated with a magnetic stainless steel wool column (Miltenyi
- 30 Biotec) and counted. Cells which did not bind to antibodies for Sca-1 passed through the column, while Sca-1<sup>+</sup> cells were retained. The Sca-1<sup>+</sup> cells were eluted from the column and both cell fractions were counted manually.

## 2. Isolation of rabbit EPC-enriched fraction from peripheral blood

Rabbit peripheral blood samples were obtained from either ear vein through a 20G infusion catheter and separated by Histopaque-1077 (Sigma) density gradient centrifugation at 400g for 20 min. The light -density mononuclear cells were harvested, washed twice by DPBS-E and counted manually. As an appropriate antibody for rabbit hematopoietic stem/precursor cells is not available, immatureHCs were isolated by depletion of matureHCs. The cells were incubated with mixed primary antibodies (Serotec) of mouse anti-rabbit CD5, anti-rabbit IgM ( $\mu$  chain) and CD11b to recognize mature T and B lymphocytes and monocytes respectively. After washing antibodies, the cells were incubated with secondary rat anti-mouse IgG microbeads (Miltenyi Biotec) and placed in a magnetic separation column (Miltenyi Biotec). Cells which did not bind to antibodies for mature T and B lymphocytes and monocytes (TBM<sup>-</sup>), identical to hematopoietic stem/precursor cells, passed through the column, while cells positive for cocktail antibodies were retained. The positive cells (TBM<sup>+</sup>), matureHCs, were eluted from the column and both cell fractions were counted manually.

## 3. EPC differentiation assay

To evaluate EPC differentiation from circulating blood cells, Sca-1<sup>+</sup> and Sca-1<sup>-</sup> cells isolated from 700 $\mu$ l peripheral blood of each mouse, as well as TBM<sup>-</sup> and TBM<sup>+</sup> cells isolated from 2 ml peripheral blood of each rabbit, were co-cultured in one well of a 24-well plate coated with rat plasma vitronectin (Sigma) after DiI-labeling of Sca-1<sup>+</sup> or TBM<sup>-</sup> cells in EBM-II media supplemented with 5% FBS (Clonetics, San Diego, CA). After four days in culture, cells were washed twice with media, and attached spreading cells were counted according to the frequency of DiI-labeled Sca-1<sup>+</sup> or TBM<sup>-</sup> cell-derived cells and non-labeled Sca-1<sup>-</sup> or TBM<sup>+</sup> cell-derived cells.

To determine the cell type of attached spindle shaped cells in the above assay, identical cells were assayed by acLDL-DiI uptake and BS-1 lectin reactivity. Double-positive cells were judged as EPCs and counted (96.2 $\pm$ 1.8% in mouse and 95.5 $\pm$ 2.4% in rabbit).

#### 4. Study design for evaluation of circulating EPC kinetics following ischemia

C57BL/6J mice (n=40) with hindlimb ischemia were sacrificed at days 0 (before surgery), 3, 7 and 14 post-operatively (10 mice at each timepoint).

- 5 Sham-operated mice were sacrificed at day 7 post-operatively as well (n=4). Peripheral blood mononuclear cells were prepared for counting of Sca-1<sup>+</sup> cells, as an EPC-enriched fraction, by magnetic bead selection (n=5) and EPC culture assay (n=5).

- 10 In New Zealand White rabbits (n=24) with hindlimb ischemia, peripheral blood mononuclear cells were isolated at post-operative days 0, 3, 7 and 14 in order to prepare for counting of TBM<sup>+</sup> cells by magnetic bead selection and EPC culture assay. Sham-operated rabbits were examined at day 7 post-operatively as well (n=4).

- 15 To evaluate the effect of ischemia-induced circulating EPCs on neovascularization, a corneal neovascularization assay (Kenyon, B.M., et al. *Invest Ophthalmol Vis Sci* (1996) and Asahara, T. et al. *Circ.Res.* (1998) was performed in mice with hindlimb ischemia. Three days after ischemia or sham surgery, C57BL/6J mice (n=5 each) underwent corneal assay microsurgery, including measurement of neovasculature length and circumference 6 days  
20 after corneal surgery (9 days after ischemia). In situ BS-1 lectin staining was performed prior to sacrifice.

#### 5. Study design for GM-CSF effect on circulating EPC kinetics and neovascularization

- 25 These experiments were intended to demonstrate the effect of GM-CSF on EPC kinetics and consequent vasculogenic contribution to neovascularization.

- 30 a. Rabbit model. Animals with hindlimb ischemia were divided into 2 groups. GM-CSF treatment, administered to 8 rabbits, consisted of recombinant human GM-CSF (70µg/ day) injected subcutaneously daily for one week, beginning 7 days before surgery (GM-CSF group). The ischemic control group consisted of 8 rabbits receiving subcutaneous injections of saline daily for one week before surgery (control group).

Rabbits were investigated on the day immediately before initial

injection (day [-]7), the day of ischemic surgery (day 0), and 3, 7, 14 days post-operatively (days 3, 7, 14), at which time peripheral blood was isolated from the central ear artery. At each timepoint, 5 ml of blood was isolated for cell counting and culture assay. In all animals from each group, the blood pressure ratio between the ischemic and healthy limb was measured and on day 14 (at sacrifice), capillary density of ischemic muscles was determined as well (vide infra).

5        b. Mouse model Following recombinant murine GM-CSF (0.5 µg/day) or control saline by i.p. injection daily for one week, beginning at day [-]7 through day [-]1, C57BL/6J mice (n=5 each) underwent corneal micropocket surgery at day 0 and the length and circumference of the consequent neovasculature was measured at day 6. In situ BS-1 lectin staining was performed before sacrifice.

#### 6. Murine bone marrow transplantation model

15        FVB/N mice underwent BMT from transgenic mice constitutively expressing  $\beta$ -galactosidase encoded by *lacZ* under the transcriptional regulation of an EC-specific promoter, Tie-2 (Schlaeger, T.m. et al. *Development* (1995). Reconstitution of the transplanted BM yielded Tie-2/LZ/BMT mice in which expression of *lacZ* is restricted to BM-derived cells  
20        expressing Tie-2; *lacZ* expression is not observed in other somatic cells. The Tie-2/LZ/BMT mice then underwent corneal assay microsurgery (Kenyon, B.M. et al. *Invest Ophthalmol Vis Sci* (1996) and (Asahara, T. et al. *Circ.Res.* (1998) , 3 days following ischemia or sham operation, or 1 day following completion of a 7-day course of GM-CSF or control vehicle.

25        BM cells were obtained by flushing the tibias and femurs of age-matched (4wk), donor Tie-2 transgenic mice (FVB/N-TgN[TIE2LacZ]182Sato, Jackson Lab). Low-density BM mononuclear cells were isolated by density centrifugation over Histopaque-1083 (Sigma). BM transplantation (BMT) was performed in FVB/N mice (Jackson Lab) lethally irradiated with 12.0 Gy and  
30        intravenously infused with approximately  $2 \times 10^6$  donor BM mononuclear cells each. At 4 wks post-BMT, by which time the BM of the recipient mice was reconstituted, the mice underwent surgery to create hindlimb ischemia (vide infra) or a sham operation; 3 days later, microsurgery for assay of corneal

neovascularization was performed. Likewise, at 4 wks post-BMT, GM-CSF or control vehicle was administered for a period of 7 days; 1 day after completion of GM-CSF or control pre-treatment, surgery for cornea neovascularization assay was performed. Corneas of BMT animals were harvested at 6 days after corneal microsurgery for light microscopic evidence of  $\beta$ -galactosidase expression or chemical detection of  $\beta$ -galactosidase activity.

#### 7. Detection of $\beta$ -galactosidase expression in corneal tissue

For histological detection of  $\beta$ -galactosidase-expressing cells, the whole eye of the mouse was enucleated, fixed in 4% paraformaldehyde for 2 hours at 4 °C, and incubated in X-gal solution overnight at 37 °C. The sample was then placed in PBS and the hemisphered cornea was excised under the dissecting microscope and embedded for histologic processing. Histologic samples were counterstained with light hematoxylin-and -eosin and examined by light microscopy to manually count the number of X-gal positive cells per cross-section. Three sections were examined from each tissue sample and averaged for evaluation of X-gal stained cell frequency.

For chemical detection of  $\beta$ -galactosidase activity, the enucleated eye was placed into liquid nitrogen, and stored at -80°C. The assay was performed using Chemiluminescence Reporter Gene Assay System, Galacto-Light Plus TM (Tropix Inc., Bedford MA) according to the modified protocol. Briefly, the eye was placed in 1 ml of supplemented lysis buffer, and after adding 0.5mM DTT was homogenized with a TissueMizer Mark II (Tekmar Co., Cincinnati, OH). Homogenized lysis solution was centrifuged to remove debris. An aliquot of the supernatant from homogenized lysis buffer was used for protein measurement using a BCA Protein Assay kit (PIERCE, Rockford, IN). The supernatant was assayed after treatment with ion exchange resin, Chelex100, and beta-galactosidase activity was measured using a chemiluminometer (Lumat LB9501, Berthold, Nashua, NH). beta-galactosidase activity was standardized according to protein concentration.

#### 8. Mouse model of hindlimb ischemia

We used age-matched (8wks) C57BL/6J male mice (Jackson Lab, Bar

Harbor, ME) to create a mouse model of hindlimb ischemia (Couffinhal, T. et al. *Am.J.Pathol* (1998). All animals were anesthetized by intraperitoneal (i.p.) pentobarbital injection (160 mg/kg) for subsequent surgical procedures. A skin incision was performed at the middle portion of the left hindlimb overlying the femoral artery. The femoral artery then was gently isolated and the proximal portion of the femoral artery was ligated with a 3-0 silk ligature. The distal portion of the saphenous artery was ligated, and other arterial branches as well as veins were all dissected free, then excised. The overlying skin was closed using two surgical staples. After surgery, mice were kept on a heating plate at 37°C, and special care was taken to monitor the animals until they had completely recovered from anesthesia.

#### 9. Rabbit model of hindlimb ischemia

We used a rabbit ischemic hindlimb model described previously (Takeshita, S. et al. *J.Clin.Invest.* (1994). A total of 20 New Zealand White rabbits (3.8-4.2 kg) (Pine Acre Rabbitry, Norton, MA) were anesthetized with a mixture of ketamine (50 mg/kg) and acepromazine (0.8 mg/kg) following premedication with xylazine (2mg/kg). A longitudinal incision was then performed, extending inferiorly from the inguinal ligament to a point just proximal to the patella. The limb in which the incision was performed was determined randomly at the time of surgery by the operator. Through this incision, using surgical loupes, the femoral artery was dissected free along its entire length; all branches of the femoral artery, including the inferior epigastric, deep femoral, lateral circumflex, and superficial epigastric, were also dissected free. After dissecting the popliteal and saphenous arteries distally, the external iliac artery and all of the above arteries were ligated with 4.0 silk (Ethicon, Sommerville, NJ). Finally, the femoral artery was completely excised from its proximal origin as a branch of the external iliac artery, to the point distally where it bifurcates to form the saphenous and popliteal arteries. Following excision of the femoral artery, retrograde propagation of thrombus leads to occlusion of the external iliac artery. Blood flow to the ischemic limb consequently becomes dependent upon collateral vessels issuing from the internal iliac artery.

#### 10. Mouse corneal neovascularization assay

Age-matched (8wk) C57BL/6J male mice (Jackson Lab) were used to evaluate mouse corneal neovascularization. All animals were anesthetized by i.p. pentobarbital injection (160 mg/kg) for subsequent surgical procedures.

- 5 Corneal micropockets were created with a modified von Graefe cataract knife in the eyes of each mouse. Into each pocket, a 0.34X0.34 mm sucrose aluminum sulfate (Bukh Meditec, Denmark) pellet coated with hydron polymer type NCC (IFN Science, New Brunswick, NJ) containing 150 ng of vascular endothelial growth factor (VEGF) was implanted. The pellets were positioned
- 10 1.0mm from the corneal limbus and erythromycin ophthalmic ointment (E.Foufura, Melville, NY) was applied to each operated eye. The corneas of all mice were routinely examined by slit-lamp biomicroscopy on postoperative days 5 through 6 after pellet implantation. Vessel length and circumference of neovascularization were measured on the sixth postoperative day when all
- 15 corneas were photographed. After these measurements, mice received 500µg of Bandeiraea Simplicifolia lectin-1 (BS-1) conjugated with FITC (Vector Lab, Burlingame, CA), an EC-specific marker, intravenously, and were then sacrificed 30 minutes later. The eyes were enucleated and fixed in 1% paraformaldehyde solution. After fixation, the corneas were placed on glass
- 20 slides and studied by fluorescent microscopy.

#### 11. Lower limb blood pressure ratio

These in vivo physiologic studies were performed on anesthetized rabbits. Blood pressure was measured in both hindlimbs. On each occasion, the

25 hindlimbs were shaved and cleaned, the pulse of the posterior tibial artery was identified with a Doppler probe, and the systolic blood pressure in each limb was measured using standard techniques. The blood pressure ratio was defined for each rabbit as the ratio of systolic pressure of the ischemic limb to the systolic pressure of the normal limb.

30

#### 12. Capillary density

The extent of neovascularization was assessed by measuring the frequency of capillaries in light microscopic sections taken from the normal and ischemic hindlimbs. Tissue specimens were obtained as transverse sections from

muscles of both limbs of each animal at the time of sacrifice. Muscle samples were embedded in O.C.T. compound (Miles, Elkhart, Ind.) and snap-frozen in liquid nitrogen. Multiple frozen sections 5  $\mu\text{m}$  in thickness were then cut from each specimen so that the muscle fibers were oriented in a transverse fashion.

- 5 The tissue sections were stained for alkaline phosphatase with an indoxyl-tetrazolium method to detect capillary ECs as previously described and counterstained with eosin. Capillaries were counted under a 20X objective to determine the capillary density (mean number of capillaries/ $\text{mm}^2$ ). Ten different fields were randomly selected for the capillary counts. The counting  
10 scheme used to compute the capillary/muscle fiber ratio was otherwise identical to that used to compute capillary density. See Prokop, D.J. (1997) *Science*, 276: 71; Perkins, S. and Fleischman, R.A. (1988) *J. Clinical Invest.* 81: 1072; Perkins, S. and Fleischman, R.A. (1990) *Blood* 75: 620.

15 13. Statistical Analysis

- All results are expressed as mean  $\pm$  standard error ( $m \pm \text{SE}$ ). Statistical significance was evaluated using unpaired Student's t test for comparisons between two means. The multiple-comparison between more than 3 groups was performed with the use of ANOVA. A value of  $p < 0.05$  was interpreted to  
20 denote statistical significance.

The following references are specifically incorporated herein by reference:

- (1) Asahara, T., Murohara, T., Sullivan, A., et al. Isolation of  
25 putative progenitor endothelial cells for angiogenesis. *Science* 275,965-967 (1997).
- (2) Folkman, J. & Klagsbrun, M. Angiogenic factors. *Science* 235,442-447 (1987).
- (3) Soldi, R., Primo, L., Brizzi, M.F., et al. Activation of JAK2 in  
30 human vascular endothelial cells by granulocyte-macrophage colony-stimulating factor. *Blood* 89,863-872 (1997).
- (4) Bussolino, F., Wang, J.M., Turrini, F., et al. Stimulation of the  $\text{Na}^+/\text{H}^+$  exchanger in human endothelial cells activated by granulocyte- and



granulocyte-macrophage-colony stimulating factor. Evidence for a role in proliferation and migration. *J.Biol. Chem.* **264**,188284-18287 (1989).

- (5) Aglietta, M., Piacibello, W., Sanavio, F., et al. Kinetics of human hematopoietic cells after in vivo administration of granulocyte-macrophage colony-stimulating factor. *J.Clin.Invest.* **83**,551-557 (1989).
- (6) Fleischman, R., Simpson, A.F., Gallardo, T., Jin, X.L. & Perkins, S. Isolation of endothelial-like stromal cells that express Kit ligand and support in vitro hematopoiesis. *Exp Hematol* **23**,1407-1416 (1995).
- (7) Flanagan, M.F., Fujii, A.M., Colan, S.D., Flanagan, R.G. & Lock, J.E. Myocardial angiogenesis and coronary perfusion in left ventricular pressure-overload hypertrophy in the young lamb: evidence for inhibition with chronic protamine administration. *Circ.Res.* **68**,1458-1470 (1991).
- (8) Takahashi, T. et al. (1998) Ischemia-and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovasularization. *Nature Medicine* **5**: 1-7.

What is claimed is:

1. A method for inducing formation of new blood vessels in a mammal, wherein the method comprises administering to the mammal an effective amount of a vascularization modulating agent sufficient to form the new blood vessels in the mammal.

- 1A. The method of claim 1, wherein the vascularization modulating agent is GM-CSF, M-CSF, b-FGF, SCF, SDF-1, G-CSF, HGF, Angiopoietin-1, Angiopoietin-2, FLT-3 ligand, or an effective fragment thereof.

10

2. The method of claim 1, wherein the vascularization modulating agent is GM-CSF, and amount of the GM-CSF administered to the mammal is sufficient to increase frequency of endothelial progenitor cells (EPC) in the mammal.

15

3. The method of claim 2, wherein the increase in frequency of the EPC is at least about 20% as determined by a standard EPC isolation assay.

4. The method of claim 1, wherein the amount of vascularization modulating agent administered to the mammal is sufficient to increase EPC differentiation in the mammal.

5. The method of claim 4, wherein the increase in EPC differentiation is at least about 20% as determined by a standard EPC culture assay.

6. The method of claim 1, wherein the amount of vascularization modulating agent administered to the mammal is sufficient to increase blood

vessel length in the mammal.

7. The method of claim 6, wherein the increase in blood vessel  
length is at least about 5% as determined by a standard blood vessel length  
5 assay.

8. The method of claim 6, wherein the amount of vascularization  
modulating agent administered to the mammal is further sufficient to increase  
blood vessel diameter in the mammal.

10

9. The method of claim 9, wherein the increase in blood vessel  
diameter is at least about 5% as determined by a standard blood vessel  
diameter assay.

10. The method of claim 1, wherein the amount of vascularization  
modulating agent administered to the mammal is sufficient to increase EPC  
differentiation following tissue ischemia.

11. The method of claim 10, wherein the increase in EPC  
20 differentiation is at least about 20% as determined by a standard hindlimb  
ischemia assay.

12. The method of claim 1, wherein the amount of administered  
vascularization modulating agent is sufficient to increase neovascularization by  
25 at least about 5% as determined by a standard cornea micropocket assay.

13. The method of claim 1, wherein the amount of administered  
vascularization modulating agent is sufficient to increase EPC bone marrow

derived EPC incorporation into foci.

14. The method of claim 13, wherein the increase in EPC bone marrow derived EPC incorporation into foci is at least about 20% as  
5 determined by a standard rodent bone marrow (BM) transplantation model.

15. The method of claim 1, wherein the mammal has, is suspected of having, or will have ischemic tissue.

- 10 16. The method of claim 15, wherein the ischemic tissue is associated with an ischemic vascular disease.

17. The method of claim 15, wherein the ischemic tissue comprises tissue from a limb, graft, or organ.

- 15 18. The method of claim 15, wherein the tissue is associated with the circulatory system or the central nervous system.

19. The method of claim 15, wherein the tissue is heart or brain  
20 tissue.

20. The method of claim 1, wherein the is co-administered with at least one angiogenic protein.

- 25 21. The method of claim 20, wherein the angiogenic protein is an endothelial cell mitogen.

22. The method of claim 20, wherein the angiogenic protein is  
acidic fibroblast growth factor (aFGF), basic fibroblast growth factor (bFGF),  
vascular endothelial growth factor (VEGF-1), epidermal growth factor (EGF),  
5 transforming growth factor  $\alpha$  and  $\beta$  (TGF- $\alpha$  and TGF- $\beta$ ), platelet-derived  
endothelial growth factor (PD-ECGF), platelet-derived growth factor (PDGF),  
tumor necrosis factor  $\alpha$  (TNF- $\alpha$ ), hepatocyte growth factor (HGF), insulin like  
growth factor (IGF), erythropoietin, colony stimulating factor (CSF),  
macrophage-CSF (M-CSF), angiopoietin-1 (Ang1) or nitric oxidesynthase  
10 (NOS); or a fragment thereof.

23. The method of claim 22, wherein the protein is one of VEGF-B,  
VEGF-C, VEGF-2, VEGF-3; or an effective fragment thereof.

15 24. A method for preventing or reducing the severity of blood  
vessel damage in a mammal, wherein the method comprises administering to  
the mammal an effective amount of granulocyte macrophage-colony  
stimulating factor (GM-CSF); and exposing the mammal to conditions  
conductive to damaging the blood vessels, the amount of GM-CSF being  
20 sufficient to prevent or reduce the severity of the blood vessel damage in the  
mammal.

25 25. The method of claim 24, wherein the conditions conducive to  
the blood vessel damage are an invasive manipulation or ischemia.

26. The method of claim 25, wherein the invasive manipulation is  
surgery.

27. The method of claim 25, wherein the ischemic is associated

with at least one of infection, trauma, graft rejection, cerebrovascular ischemia, renal ischemia, pulmonary ischemia, limb ischemia, ischemic cardiomyopathy, or myocardial ischemia.

5           28.     The method of claim 24, wherein the GM-CSF is administered to the mammal at least about 12 hours before exposing the mammal to the conditions conducive to damaging the blood vessels.

10           29.     The method of claim 28, wherein the GM-CSF is administered to the mammal between from about 1 to 10 days before exposing the mammal to the conditions conducive to damaging the blood vessels.

15           30.     The method of claim 28, wherein the method further comprises administering the GM-CSF to the mammal following the exposure to the conditions conducive to damaging the blood vessels.

31.     A method for treating ischemic tissue in a mammal in need of such treatment, wherein the method comprises:

- a) isolating endothelial progenitor cells (EPCs) from the mammal,
- 20       b) contacting the isolated EPCs with an amount of an angiogenic protein sufficient to induce proliferation of the EPCs; and
- c) administering the proliferated EPCs to the mammal in an amount sufficient to treat the ischemic tissue.

25           32.     The method of claim 31, wherein the EPCs have at least one of the following markers: CD34<sup>+</sup>, flk-1<sup>+</sup> or tie-2<sup>+</sup>.

33. The method of claim 31, wherein the ischemic tissue comprises injured blood vessels.

34. The method of claim 33, wherein the blood vessels are injured  
5 by an invasive manipulation.

35. The method of claim 34, wherein the invasive manipulation is balloon angioplasty, or deployment of a stent or catheter.

10 36. The method of claim 35, wherein the stent is an endovascular stent.

37. The method of claim 31 further comprising co-administering at least one angiogenic protein.

15

38. The method of claim 37, wherein the angiogenic protein is an endothelial cell mitogen or a nucleic acid encoding the endothelial cell mitogen.

20 39. The method of claim 38, wherein the angiogenic protein is acidic fibroblast growth factor (aFGF), basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF-1), epidermal growth factor (EGF), transforming growth factor  $\alpha$  and  $\beta$  (TGF- $\alpha$  and TGF- $\beta$ ), platelet-derived endothelial growth factor (PD-ECGF), platelet-derived growth factor (PDGF),  
25 tumor necrosis factor  $\alpha$  (TNF- $\alpha$ ), hepatocyte growth factor (HGF), insulin like growth factor (IGF), erythropoietin, colony stimulating factor (CSF), macrophage-CSF (M-CSF), angiopoietin-1 (Ang1) or nitric oxidesynthase (NOS); or a fragment thereof.

40. The method of claim 39, wherein the protein is one of VEGF-B, VEGF-C, VEGF-2, VEGF-3; or a fragment thereof.

5 41. A method for detecting presence of tissue damage in a mammal, wherein the method comprises contacting the mammal with a detectably-labeled population of endothelial progenitor cells (EPCs); and detecting the labeled cells at or near the site of the tissue damage in the mammal.

10 42. The method of claim 41, wherein the tissue damage is ischemia or an ischemic vascular disease.

43. A pharmaceutical product for inducing neovascularization in a mammal, wherein the product comprises isolated endothelial progenitor cells  
15 (EPCs) and is formulated to be physiologically acceptable to a mammal.

44. The pharmaceutical product of claim 43, wherein the product is sterile and further comprises at least one angiogenic protein or nucleic acid encoding the protein.

20

45. A kit for the systemic introduction of a isolated endothelial progenitor cells (EPCs), wherein the kit comprises the isolated EPCs and optionally at least one angiogenic protein or nucleic acid encoding same, the kit further optionally comprising a pharmacologically acceptable carrier  
25 solution, nucleic acid or mitogen, means for delivering the EPCs and directions for using the kit.



46. The kit of claim 45, wherein the means for delivering the EPCs is a stent, catheter or syringe.


47. A method for enhancing endothelial progenitor cell (EPC) mobilization in a mammal, wherein the method comprises administering an effective amount of at least one hematopoietic factor sufficient to enhance the EPC mobilization in the mammal.

48. The method of claim 47 further comprising co-administering to the mammal an effective amount of one or more of: granulocyte macrophage-colony stimulating factor (GM-CSF); at least one angiogenic protein; or an effective fragment thereof.

# ABSTRACT

The present invention generally provides methods for modulating formation of new blood vessels. In one embodiment, the methods include administering to a mammal an effective amount of granulocyte macrophage-colony stimulating factor (GM-CSF) sufficient to form the new blood vessels. Additionally provided are methods for preventing or reducing the severity of blood vessel damage in a mammal which methods preferably include administering to the mammal an effective amount of GM-CSF. Provided also as part of this invention are pharmaceutical products and kits for inducing formation of new blood vessels in the mammal.

#122145



Figures 1A-1D




Figure 2A

Figure 2B




Figure 3A




Figure 3B




Figure 3C



Figure 4A




Figure 4B




Figure 4C




Figure 4D



Figure 4E




Figure 4F



Figure 4G




Figure 4H



Figure 4I



Figure 4J



002257-32266 Ischemia

Sham



Figure 5D

Figure 5C





Fig 5 E

Fig 5 F




Figure 5G




Figure 5H






Figure 6B




Figure 6A

Figure 6C

Control




Figure 6D

GMCSF



Figure 6E

F




Figure 6F

G




Figure 6G

I

H




Figure 6H




Figure 6I




Figure 7A




Figure 7B




Figure 7C



I hereby claim the benefit under 35 U.S.C. §120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below, and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose material information as defined in 37 CFR §1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:

Prior U.S. Applications or PCT International Applications Designating the U.S.-Benefit Under 35 U.S.C. §120				
U.S. Applications		Status (Check One)		
Application Serial No.	U.S. Filing Date	Patented	Pending	Abandoned
PCT Applications Designating the U.S.				
Application No.	Filing Date	U.S. Serial No. Assigned		

**CLAIM FOR BENEFIT OF PRIOR U.S. PROVISIONAL APPLICATION(S)**  
(35 U.S.C. § 119(e))

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below:

Applicant	Provisional Application Number	Filing Date
Jeffrey M. Isner, et al.	60/077,262	March 9, 1998

**POWER OF ATTORNEY:** As a named inventor, I hereby appoint the following attorney(s) with full powers of association, substitution and revocation to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Sewell P. Bronstein (Reg. No. 16,919)  
David G. Conlin (Reg. No. 27,026)  
George W. Neuner (Reg. No. 26,964)  
Linda M. Buckley (Reg. No. 31,003)  
Peter F. Corless (Reg. No. 33,860)

Peter J. Manus (Reg. No. 26,766)  
Cara Z. Lowen (Reg. No. 38,227)  
William J. Daley, Jr. (Reg. No. 35,487)  
Robert L. Buchanan (Reg. No. 40,927)  
Christine C. O'Day (Reg. No. 38,256)

<b>SEND CORRESPONDENCE TO:</b> Robert L. Buchanan Dike, Bronstein, Roberts & Cushman, LLP 130 Water Street Boston, Massachusetts 02109	<b>DIRECT TELEPHONE CALLS TO:</b> Robert L. Buchanan  (617) 523-3400
--	---

FULL NAME OF INVENTOR	LAST NAME	FIRST NAME	MIDDLE NAME
	Isner	Jeffrey	M.
RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	Weston	Massachusetts	USA
POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY AND ZIP CODE
	34 Brenton Road	Weston	MA 02193

FULL NAME OF INVENTOR	LAST NAME	FIRST NAME	MIDDLE NAME
	Asahara	Takayuki	
RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	Arlington	Massachusetts	Japan
POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY AND ZIP CODE
	38 Hayes Street	Arlington	MA 02174

FULL NAME OF INVENTOR	LAST NAME	FIRST NAME	MIDDLE NAME
RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY AND ZIP CODE

FULL NAME OF INVENTOR	LAST NAME	FIRST NAME	MIDDLE NAME
RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY AND ZIP CODE

1 2 3	FULL NAME OF INVENTOR	LAST NAME	FIRST NAME	MIDDLE NAME
1 2 3	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY AND ZIP CODE

1 2 3	FULL NAME OF INVENTOR	LAST NAME	FIRST NAME	MIDDLE NAME
1 2 3	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY AND ZIP CODE

1 2 3	FULL NAME OF INVENTOR	LAST NAME	FIRST NAME	MIDDLE NAME
1 2 3	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY AND ZIP CODE


1 2 3	FULL NAME OF INVENTOR	LAST NAME	FIRST NAME	MIDDLE NAME
1 2 3	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY AND ZIP CODE

I hereby further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Signature of Inventor 201	Signature of Inventor 202
Date: <i>Jeffrey Jara MD</i>	Date: <i>John Li</i>



United States Patent & Trademark Office  
Office of Initial Patent Examination -- Scanning Division



Application deficiencies were found during scanning:

☐ Page(s) \_\_\_\_\_ of \_\_\_\_\_ were not present  
for scanning. (Document title)

☐ Page(s) \_\_\_\_\_ of \_\_\_\_\_ were not present  
for scanning. (Document title)

☒ Scanned copy is best available. *Drawings.*